RESI CONFERENCE

REDEFINING EVERY STAGE OF INVESTMENT *SEED TO EXIT*

RESI JPM 2026

JAN 12-13 | SAN FRANCISCO, CA

JAN 14, 19-20 | VIRTUAL PARTNERING

PRESENTED BY

LIFE SCIENCE NATION
Connecting Products, Services & Capital

ONSITE GUIDE

brisbane australia

Enterprise Singapore

BioMeta Advancing your discovery

Capital investors, licensing partners, fundraising CEOs, and service providers Make a Compelling Connection

RESIConference.com | San Francisco Marriott Marquis

#RESI #RESIJPM

RESI

2026 CONFERENCE SERIES

RESI EUROPE 2026

MAR 23: LISBON, PORTUGAL
MAR 24-25: VIRTUAL PARTNERING

RESI JUNE 2026

JUNE 22: SAN DIEGO, CA
JUNE 23-24: VIRTUAL PARTNERING

RESI BOSTON 2026

SEPT 22-23: BOSTON, MA
SEPT 25, 28: VIRTUAL PARTNERING

Take $100 off with discount code **RESI100** for future RESIs.

For more information about our future events,

visit our website RESIConference.com or contact us at RESI@lifesciencenation.com.

CONTENT

RESI JPM 2026

WELCOME TO RESI

Welcome to Redefining Every Stage of Investments (RESI) JPM 2026 at the San Francisco Marriott Marquis

Life Science Nation (LSN) is proud to host our 50th RESI Conference, welcoming a global community of capital investors, licensing strategic partners, and life science entrepreneurs.

This year, RESI JPM takes place over two days, offering a packed schedule of investor panels, workshops, and two Innovator's Pitch Challenge (IPC) tracks. IPC finalists will pitch directly to a live audience and a panel of relevant investor judges.

Attendees can also 'invest' their RESI cash and learn more about each company through their poster displays in the Golden Gate B Hall. Winners of the IPC will be announced during the celebratory cocktail reception at the end of the conference.

RESI JPM 2026 also provides an opportunity to connect with tech hubs, service providers, and mission-driven organizations that help life science companies succeed in fundraising and beyond. Learn from these players through educational sessions and exhibits, and explore dynamic networking receptions to discover new and inspiring ways to connect with strategic partners.

LSN extends our sincere thanks to our **Title Sponsors: Enterprise Singapore, BEDA Brisbane Economic Development Agency, and Biometas**, whose support has been instrumental in bringing together this global life science community. We also thank our **Gold Sponsors: KBIC, Medmarc, One Nucleus, o2H Group, HiRO, Israel Export Institute, and Queensland Government. Silver Sponsor: TrilliumBiO, Catalyze, and Bronze Sponsor: Polsinelli**. Their contributions help make RESI JPM a milestone event in the life science investment calendar.

At its core, RESI is designed to connect life science companies with capital, licensing, and channel partners that match their product and stage of development primarily through RESI Partnering. This global platform allows attendees to book meetings based on detailed criteria, ensuring well-fitting connections. Partnering occurs in person on Monday, January 12, and Tuesday, January 13, with virtual partnering continuing through Wednesday, January 14, and an additional days on Monday, January 19 and Tuesday, January 20.

Sougato Das
President and Chief Operating Officer
Life Science Nation

LIFE SCIENCE NATION
Connecting Products, Services & Capital

SAN FRANCISCO MARRIOTT MARQUIS
GOLDEN GATE HALL

January 12
1-2PM NAUGEN: Global Innovation Accelerator and Portfolio Showcase

January 13
11AM-12PM Israel Export Institute: Israel Company Showcase

12-4PM O2h: Cambridge x London Life Sciences Showcase

January 12
9AM-12PM BEDA: Investor Innovation Showcase - JPM Week 2026

January 13
12-2PM KBIC:Kansai Life Science Accelerator Program (KLSAP) Demo Day



WiFi: RESI_JPM
PW: resi2026

Sponsors & Exhibitors

1 AdvaMed
2 OneNucleus
3 Apex/abiquifi
4,5 Life Science Nation
6 HiRO
7 Israel Export Institute
8 BioMetas
9 Enterprise Singapore
10 O2H
12 Dash Bio
13 Catalyze
14 Medmarc
15 Opis
16 TrilliumBiO
17 Novotech
18 Polsinelli
19 Inertia
20 Venture Valuation
21 Trade and Investment Queensland
22 NAUGEN
23 BEDA
27 Kobe Biomedical Innovation Cluster

Pitching Company Table

1 Aevice Health
2 Roceso Technologies
3 NousQ
4 VerImmune
5 REVIVO BioSystems
6 Rosalind Dx
7 KYAN Technologies
8 ChemT Biotechnology
9 STARCO
10 QBiotics Group Limited
11 Aptium AI
12 LORAI Health

Pitching Company Table

13 Fibrosoft
14 Ketim Technologies
15 Proseek Bio
16 Cool Beans Underwear
17 Bivacor
18 Talius
19 Tidewave Biotech
20 Pure Green Pharmaceuticals
21 Huna AI
22 Gen-T
23 CNPen
24 Biolinker
25 Nintx
26 BASH
27 Orby
28 Telavita
29 Aurenar
30 ATDev
31 HOPO Therapeutics
32 Arkayli Biopharma
33 MiRNDa
34 Celaid Therapeutics
35 Great Bay Bio
36 28bio
37 CoraVie Medical
38 Molecular You
39 Inomagen Therapeutics
40 IsletRegen
41 AlphaOnco
42 KAHR Medical
43 GI Bionics
44 BMI OrganBank
45 NeuroHope Therapeutics
46 Repair Biotechnologies
47 Animate Biosciences
48 Alphyn Biologics
49 JangoBio
50 Immunis
51 Orange Biomed
52 Frontier Bio
53 InStatin
54 Delphian Therapeutics
55 Galibra Neuroscience
56 VitalTE Life Sciences
57 PranaQ
58 Transformative Biotech
59 eSensorem
60 nSight Surgical
61 DARWIN Biomed
62 Opportunity Health
63 Fischer Imaging
64 Adaptyx Biosciences
65 Nanogrow Biotech
66 Retroviral Proviromics
67 DyoGel
68 VenstraMedical
69 BioSuperior Technology
70 ilerabio
71 Monod Bio
72 Multus Biotechnology
73 Biosortia
74 Immorta Bio
75 Sunac Tx
76 TesoRx Pharma
77 Rapid Infection Diagnostics
78 Imaginostics
79 Sebastian Biopharma
80 BCN Biosciences
81 Bayou Surgical
82 Blend Health Technologies
83 i-Lumen Scientific
84 Brain4Care
85 PlusVitech
86 ReEngage Therapeutics
87 Ad Astra Diagnostics
88 DetellaDx
89 Hemeo
90 CygnusMed
91 iQure Pharma
92 ONCOVITA
93 Kilele Health
94 Eva Scientific
95 CDR3 Therapeutics
96 Pharma in silica

EXHIBIT TABLES

Location: Golden Gate Foyer & Gate B

THE MEDTECH CONFERENCE OCT 18-21 | BOSTON, MA AdvaMed	one nucleus	apexBrasil	LIFE SCIENCE NATION Connecting Products, Services & Capital
Table# 1	Table# 2	Table# 3	Table# 4,5
HiRO	ISRAEL EXPORT INSTITUTE	BioMeta Advancing your discovery	Enterprise Singapore
Table# 6	Table# 7	Table# 8	Table# 9
o2h discovery	DASH	CATALYZE Accelerating Translation	MEDMARC LIFE SCIENCES INSURANCE
Table# 10	Table# 12	Table# 13	Table# 14
OPIS A Science Driven Biotech Focused CRO	TRILLIUMBIO	NOVOTECH Biotech's Partner at Every Phase	POLSINELLI What a law firm *should* be.™
Table# 15	Table# 16	Table# 17	Table# 18
inertia	BIOTECH GATE BUSINESS DEVELOPMENT DATABASE VENTURE VALUATION	Queensland Government TIQ TRADE + INVESTMENT QUEENSLAND	NAUGEN
Table# 19	Table# 20	Table# 21	Table# 22
brisbane australia	KBIC KOBE Biomedical Innovation Cluster		
Table# 23	Table# 27		

INNOVATOR'S PITCH CHALLENGE

Location: Golden Gate B

aevice health Table #1	ROCESO TECHNOLOGIES Table #2	NousQ Table #3	VERIMMUNE Table #4	REVIVO BioSystems Table #5
ROSALIND DX PRENATAL TESTING FOR ALL Table #6	KYAN TECHNOLOGIES Table #7	ChemT Biotech Table #8	STARCO Table #9	QBiotics Group Table #10
aptium Table #11	LORAI Table #12	Fibrosoft Table #13	Ketim Table #14	Proseek bio. Table #15
COOLBEANS MEN'S HEALTH UNDERWEAR Table #16	BIVACOR Table #17	Talius Table #18	TIDEWAVE BIO ADVANCED CELL TECHNOLOGY Table #19	PG PURE GREEN PHARMACEUTICALS Table #20
huna Table #21	gen-t Table #22	CNPEM Brazilian Center for Research in Energy and Materials Table #23	BIO LINKER Table #24	Nintx Table #25
BASH Table #26	Orby.co Table #27	Telavita Table #28	AURENAR Table #29	ATDev Table #30
HOPO THERAPEUTICS Table #31	ARKAYLI BIOPHARMA Table #32	MiRNDa Table #33	Celaid Therapeutics Table #34	GBB Great Bay Bio AI Advance Bioprocessing Table #35

INNOVATOR'S PITCH CHALLENGE

Location: Golden Gate B

28bio™	CoraVie MEDICAL	molecular you	inomagen™	islet REGEN
Table #36	Table #37	Table #38	Table #39	Table #40
AlphaOnco A Natural Nanomedicine For Cancer Treatment	IMMUNITY. RECRUITED.	GIBionics™ NextGen Medical Devices	BMI OrganBank®	NeuroHope Therapeutics, Inc.
Table #41	Table #42	Table #43	Table #44	Table #45
Repair Biotechnologies	ANIMATE BIOSCIENCES	ALPHYN BIOLOGICS	JangoBio® Living healthier lives, longer	Immunis
Table #46	Table #47	Table #48	Table #49	Table #50
ORANGE BIOMED	FRONTIER BIO	InStatin Inc	Delphian Therapeutics	GALIBRA NEUROSCIENCE
Table #51	Table #52	Table #53	Table #54	Table #55
VitalTE REDUCING COMPLEXITY WITH EFFECTIVE HORMONE DELIVERY	pranaQ®	Transformative Biotech	eSensorem	nSight Surgical
Table #56	Table #57	Table #58	Table #59	Table #60
DARWIN BIOMED®	OPPORTUNITY HEALTH	FISCHER IMAGING BETTER IMAGING, BETTER OUTCOMES	Adaptyx	NANO GROW small biomolecules, big solutions
Table #61	Table #62	Table #63	Table #64	Table #65
RETROVIRAL PROVIROMICS	DyoGel	VENSTRA MEDICAL	bio superior	Ilerabio
Table #66	Table #67	Table #68	Table #69	Table #70

INNOVATOR'S PITCH CHALLENGE

Location: Golden Gate B

MONOD BIO Table #71	MULTUS BETTER MEDIA. BY DESIGN Table #72	Biosortia Table #73	IMMORTA BIO A Scientific Longevity Company Table #74	SUNAC THERAPEUTICS Table #75
TesoRx Table #76	RID INC. Table #77	imaginostics Table #78	BP Sebastian BioPharma Table #79	BCN Table #80
Bayou surgical Table #81	Blend Table #82	i-Lumen Scientific ADVANCING VISION RESTORATION Table #83	brain4care Table #84	Plus Vitech Table #85
ReEngage Therapeutics Table #86	AAD Ad Astra Diagnostics Table #87	DetellaDX KNOWING EARLY TO WIN Table #88	HEMEO KNOW THE FLOW Table #89	CygnusMed, Inc. Table #90
iQure Table #91	ONCOVITA Table #92	KILELE HEALTH Table #93	Eva SCIENTIFIC Table #94	CDR3 Therapeutics Table #95
PHARMA IN SILICA INC Table #96				

Vote for Your Favorite Technology

Conference attendees will be given "RESI Cash" upon entry to invest in the companies they find most compelling throughout the entire 2 days of the in-person RESI. Top 3 companies with the most RESI Cash "invested" are announced during the closing networking reception.

- 1st Place – Complimentary tickets to 3 RESI events of your choice (up to 2 tickets per event)
- 2nd Place – Complimentary tickets to 2 RESI events of your choice (up to 2 tickets per event)
- 3rd Place – Complimentary tickets to 1 RESI event of your choice (up to 2 tickets per event)

JANUARY 12 - AGENDA

7:00 AM – 8:00 AM: **Breakfast Buffet (Ballroom Foyer)**
8:00 AM – 5:00 PM: **Onsite Partnering (Golden Gate A)**

	Investor Panels (Golden Gate C1)	Innovator's Pitch Challenge: Track 1 (Golden Gate C2)	Innovator's Pitch Challenge: Track 2 (Golden Gate C3)	Entrepreneur's Workshops (Golden Gate B)
9:00 AM - 9:50 AM	**"FIRST CHECK" VCS** *Backing Founders at the Very Beginning*	**SESSION #1 THERAPEUTICS** *Backing Founders at the Very Beginning*	**brisbane australia** **9AM - 12:00PM** **INVESTOR INNOVATION SHOWCASE - JPM WEEK 2026** By Brisbane Economic Development Agency	**NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS**
10:00 AM - 10:50 AM	**MEDTECH STRATEGICS** *Driving Growth Through Strategic Partnerships and Acquisitions*	**SESSION #2 THERAPEUTICS** *Next Generation Oncology Therapeutics*		NOVOTECH™ **THE FAST LANE TO POC** *Leveraging Australia and China for Smarter Early Clinical Development*
11:00 AM - 11:50 AM	**ASIA CROSS BORDER INVESTMENTS** Enterprise Singapore	**SESSION #3 THERAPEUTICS** *Chronic Disease and Inflammation*		VENTURE VALUATION GLOBAL VALUATION SERVICES **COMPANY VALUATION FOR FUNDRAISING**
12:00 - 1:00 PM: **Lunch Break (Ballroom Foyer)**			Queensland Government TIQ TRADE + INVESTMENT QUEENSLAND **CONDUCTING CLINICAL TRIALS IN AUSTRALIA POWERED BY QUEENSLAND GOVERNMENT**	
1:00 PM - 1:50 PM	**FAMILY OFFICES** *Patient Capital with a Personalized Approach*	**SESSION #4 THERAPEUTICS** *Neurology & CNS*	**SESSION #5 MEDICAL DEVICES** *Therapeutic & Rehabilitation Devices*	NAUGEN **GLOBAL INNOVATION ACCELERATOR AND PORTFOLIO SHOWCASE**
2:00 PM - 2:50 PM	**CELL & GENE THERAPY** *Investing in the Next Frontier of Medicine*	**SESSION #6 MEDICAL DEVICES** *Surgical & Procedural Innovations*	**SESSION #7 DIAGNOSTICS** *Rapid Point-of-Care Diagnostics*	**TALES FROM THE ROAD** *Biotech and MedTech Innovators on their Fundraising Journey*
3:00 PM - 3:50 PM	**WHEN SHOULD COMPANIES EXIT STEALTH MODE?** *Timing the Transition from Quiet Development to Public Visibility*	**SESSION #8 THERAPEUTICS** *Advanced Cell & Gene Therapies*	**SESSION #9 MEDICAL DEVICES** *Cardiovascular Support & Monitoring Devices*	Magnet Venture **AI DRUG DISCOVERY 2026: THE RISE, THE PIVOT, AND THE PIPELINE**
4:00 PM - 4:50 PM	**AGING AND LONGEVITY** *Investing in Solutions for the World's Aging Population*	**SESSION #10 THERAPEUTICS** *Therapies for Chronic & Specialized Conditions*	**SESSION #11 ENABLING TECHNOLOGIES** *Innovations in Imaging, Biosensing & Molecular Platforms*	

JANUARY 13 - AGENDA

7:00 AM – 8:00 AM: **Breakfast Buffet (Ballroom Foyer)**
8:00 AM – 5:00 PM: **Onsite Partnering (Golden Gate A)**

	Investor Panels (Golden Gate C1)	Innovator's Pitch Challenge: Track 1 (Golden Gate C2)	Innovator's Pitch Challenge: Track 2 (Golden Gate C3)	Entrepreneur's Workshops (Golden Gate B)
9:00 AM - 9:50 AM	**PARTNERING WITH GLOBAL PHARMA** *How Big Pharma Impacts Early Stage Innovation*	**SESSION #12** **R&D AND DIGITAL HEALTH TECHNOLOGIES** *Clinical Intelligence & Predictive Modeling Platforms*	**SESSION #13** **DIAGNOSTICS** *AI-Enabled Imaging & Multi-Omics*	apexBrasil **CHANGING THE LANDSCAPE FOR VENTURE CAPITAL FOR LIFE SCIENCES IN BRASIL**
10:00 AM - 10:50 AM	**WOMEN'S HEALTH** *Investing in an Underserved Market with Enormous Potential*	**SESSION #14** **THERAPEUTICS** *Targeted Oncology Therapies*	**SESSION #15** **MEDICAL DEVICES** *Chronic Disease & Functional Monitoring*	HiRO **LEVERAGING ASIA: HOW TO NAVIGATE ASIAN VC INVESTMENT MANDATES**
11:00 AM - 11:50 AM	**AI IN HEALTHCARE** *Redefining R&D and Care Delivery with Artificial Intelligence*	**SESSION #16** **THERAPEUTICS** *Chronic Disease & Functional Monitoring*	**SESSION #17** **THERAPEUTICS** *Novel Approaches to Restore Biological Function*	ISRAEL EXPORT INSTITUTE **ISRAEL COMPANY SHOWCASE**
12:00 - 1:00 PM: **Lunch Break (Ballroom Foyer)**			**12 - 2PM** **KANSAI LIFE SCIENCE ACCELERATOR PROGRAM (KLSAP) DEMO DAY** By Kobe Biomedical Innovation Cluster	o2h discovery **12 - 4PM** **CAMBRIDGE X LONDON LIFE SCIENCES SHOWCASE** By o2h Discovery
1:00 PM - 1:50 PM	**ORPHAN & RARE DISEASES** *Unlocking Innovation for High-Need, Niche Markets*	**SESSION #18** **DIAGNOSTICS** *Women's Health and Precision Health*		
2:00 PM - 2:50 PM	**CORPORATE VC** *Strategic Investment Beyond the Balance Sheet*	**SESSION #19** **MEDICAL DEVICES** *Physiologic Modulation Devices*	**SESSION #20** **R&D AND LIFE SCIENCE TOOLS** *Biomanufacturing & Biologics Innovation*	
3:00 PM - 3:50 PM	**TECHBIO & SYNTHETIC BIOLOGY** *Engineering Biology for the Next Wave of Innovation*	**SESSION #21** **DIAGNOSTICS** *Novel Diagnostics & Clinical Decision Tools*	**SESSION #22** **R&D AND LIFE SCIENCE TOOLS** *Enabling Platforms for Therapeutic Development*	
4:00 PM - 4:50 PM	**2026 OUTLOOK: VC PERSPECTIVES** *Where Investors See Healthcare Innovation Headed*	**SESSION #23** **THERAPEUTICS** *Emerging Therapies & Targeted Interventions*	**SESSION #24** **DEVICES & DIGITAL HEALTH** *Advancing Clinical Care Delivery*	

5:00 - 7:00 PM: **Cocktail Reception - IPC Winners Announced (Ballroom Foyer)**

Why Singapore

Singapore's healthcare and biomedical industry is vibrant and growing, anchored on strong fundamentals:

- Thriving Research & Development ecosystem with strong base of innovative startups
- Robust community of deep tech investors
- Deep base of skilled talent
- Sound financial and trading infrastructure
- Strong government support

Join us at the panel discussion on **Asia Cross Border Investments happening on 12 Jan at 11am** to learn more about investing in Singapore and Asia.

Looking for your next investment? **Meet our Singapore startups at Golden Gate C2/C3 Rooms**, and RESI JPM partnering platform at www.hellopartnering.com

Enterprise Singapore

For where you're growing

Investor Innovation Showcase - JPM Week 2026

By powered by Brisbane Economic Development Agency (BEDA)

and Trade and Investment Queensland (TIQ)

San Francisco Marriott Marquis - Golden Gate C3

January 12 from 9am to 12:00pm

Brisbane Economic Development Agency (BEDA) in collaboration with Trade and Investment Queensland (TIQ) and Life Science Nation (LSN) extends an invitation of attendance for investors at this exclusive Innovation Showcase taking place during J.P. Morgan Healthcare Week 2026.This focused Investor Innovation Showcase is presented in collaboration with Life Science Nation at RESI JPM 26 reserved for attending investor audience. Hear from a selection of leading-edge Australian medical device, diagnostic, therapeutic and digital health innovators as they seek investment opportunities and global strategic partnerships. Refer to the Investment Ready MedTech Innovation Showcase from the presenting companies. We eagerly anticipate showcasing Australia's most promising, global class advancements in medical innovation and fostering global collaboration.

brisbane australia

Queensland Government

TIQ TRADE + INVESTMENT QUEENSLAND

Conducting Clinical Trials in Australia

By powered by Brisbane Economic Development Agency (BEDA)

and Trade and Investment Queensland (TIQ)

San Francisco Marriott Marquis - Golden Gate C3

January 12 from 12pm to 1pm

Convened jointly by the Queensland Government (QG) and the Brisbane Economic Development Agency (BEDA) during JPM Week 2026, this event will present a coordinated, end-to-end view of Australia's clinical trials and translational capability, with a focus on Queensland and Brisbane. It is designed as a targeted engagement for international biopharma companies, investors and partners attending JPM and RESI JPM.

The session will outline why Australia is a competitive destination for global clinical development, highlighting speed to clinic, data quality, cost competitiveness, and internationally recognized regulatory pathways. It will provide practical insight into how sponsors can establish, deliver, and scale clinical programs in Australia.

brisbane
australia

Choose Brisbane

To Choose Brisbane is to choose Australia. As the 12th largest economy in the world, underpinned by stable governance and 17 Free Trade Agreements, Australia is an unbeatable launchpad for companies looking to expand into the Asia Pacific region.

Brisbane is a leading economic powerhouse recognised as the fastest growing major capital city, with an economy projected to grow to $275 billion by 2041. Brisbane is Australia's gateway to the Asia Pacific, boasting the closest proximity to the world's economic growth engine.

Brisbane's Health Economy

Brisbane's health ecosystem is a leading destination for clinical trials, commercialisation and export-led growth, backed by significant public investment. The city hosts the largest health cluster in the Southern Hemisphere, offering world-class education and research, strong government support, Australia's highest density of innovation hubs and a rapidly growing export sector.

- **Clinical trials:** Supported by advanced research infrastructure and a diverse population, Brisbane delivers trials at a cost up to 60% lower than the U.S.
- **Health supply chains:** Major health capital investment and expanding operations are creating new opportunities for private-sector suppliers.
- **MedTech/BioTech commercialisation:** Cutting-edge research and a highly supportive ecosystem position Brisbane as a hotspot for commercialisation.

Brisbane is a leader in medical innovation, producing more than 6,700 health-related graduates each year across medicine, biomedical sciences, engineering, nursing and allied health - feeding into a 190,000-strong health workforce.

#1 **Fastest Growing Major Australian capital city over 10 years**
Working age population (25-49 years)

$18B **Health Infrastructure Pipeline**

Largest Healthcare Precinct
Within Southern Hemisphere

Australia's #1 University - Biotechnology
The University of Queensland

Top 40 **Global Innovation City**
Home to more than 140 innovation hubs

ABOUT BRISBANE ECONOMIC DEVELOPMENT AGENCY

Brisbane Economic Development Agency (BEDA) drives investment demand in Brisbane, supporting potential global investors with full market entry strategies. As Brisbane's champion - BEDA works with government and private sector organizations to support global investors to leverage economic opportunities within Brisbane.

Scan the QR code to access the city's Health Prospectus and information on companies and projects.

e: investmentattraction@brisbane-eda.com.au
p: +61 7 3006 6200 | w: choose.brisbane.qld.au

Kobe Biomedical Innovation Cluster

Japan's Leading Life Science Hub

KBIC project started as one of the earthquake disaster reconstruction projects in the aftermath of Great Hanshin-Awaji Earthquake in 1995. KBIC took on the task of forging a foundation for the healthcare industry and has grown to be a leading biomedical hub in Japan.

350+
Companies / Organization



3 Subclusters to Facilitate Healthcare Innovation



Medical Cluster — 8 highly specialized medical institutions


Kobe City Medical Center General Hospital

Bio Cluster — RIKEN and prominent research institutions


RIKEN Center for Biosystems Dynamics Research (BDR)

Simulation Cluster — Supercomputer FUGAKU and related institutions


Supercomputer Fugaku

Companies in KBIC

Join us at KBIC Session @ RESI JPM 2026!

KBIC
KOBE Biomedical Innovation Cluster

January 13, 12:00–2:00pm PST

Golden Gate C3 Room, Marriott Marquis San Francisco

G-BIOMEX
GENEMEDICINE
iXgene
aceRNA Technologies
Celaid Therapeutics
CellFiber
CynosBio
FerroptoCure
LM LinqMed Inc.
PROGENICYTE JAPAN
Quadlytics

JPM HEALTHCARE WEEK 2026

Cambridge x London Life Sciences Showcase

13th Jan, Tue | 12:00 PM - 4:00 PM

RESI Conference, Marriott Marquis, San Francisco (SFO)

Sponsored by

CAMBRIDGESHIRE & PETERBOROUGH COMBINED AUTHORITY | PAUL BRISTOW MAYOR OF CAMBRIDGESHIRE & PETERBOROUGH

o2h ventures . discovery . tech

wellcome | WELLCOME GENOME CAMPUS

CANCER RESEARCH HORIZONS

Mishcon de Reya

CAMBRIDGE UNIVERSITY Health Partners

Agenda

12:00 PM	Registration
12:30 PM	Welcome and Keynotes
1:00 PM	Pitch Sessions
2:30 PM	Informal Networking

Register to

Pitch as a presenting company, contact us at ajit@o2h.com by 10th Dec 2025 (midnight)

Attend, contact us at info@o2h.com by 12th Jan 2026 (midday)

Overview

We are delighted to launch the first-ever Cambridge x London Life Sciences Showcase as part of RESI JPM Healthcare Week 2026. The event will be a unique platform spotlighting some of Cambridge & London's most innovative and pioneering life sciences, biotech, deeptech, and techbio companies, giving them the chance to present their innovations globally, while fostering meaningful engagement between founders and investors. The event will bring together leading voices from Cambridge & London's thriving life sciences ecosystems, with special keynote speeches from Steve Bates (Office for Life Science UK Government), Andy Richards (Serial Entrepreneur and Investor), and Tony Jones (CEO, One Nucleus), alongside others including ministerial attendance.

The showcase will feature 20 company 'flash' pitches. We will structure the pitches into three groups, series A/B+, pre-seed and then seed. The pitches shall be interspersed with networking opportunities. The schedule will end with an extended informal session where investors can engage directly with presenting companies. The format is designed to highlight what makes these two ecosystems uniquely positioned at the forefront of global life sciences innovation.

Apply to Pitch

We welcome applications from innovative life science companies at all stages from pre-seed, seed through Series A/B+.

Please apply via this link - [click here] or write us at ajit@o2h.com

The deadline for applications from companies is Wednesday, 10th December 2025 (midnight).

To Attend as Delegate

We welcome delegates interested in meeting pioneering life sciences, biotech, deeptech, and techbio founders from across the Cambridge and London ecosystems.

Please register via this link - [click here] or write us at info@o2h.com

The link for attending the showcase shall close when the event is full or by midday 12th Jan 2026.

Disclaimer: By registering through "link or email" your details will be added to the attendee list, which will be shared with the organisers and sponsors solely for event planning purposes. Your personal data will be processed in accordance with applicable data protection and privacy laws, including the Data Protection Act 2018, UK GDPR, and EU GDPR, as relevant.

For more information, please refer to the privacy policies available on each organisation's website.

Contact Info: Should you have any questions, please feel free to reach us at info@o2h.com

NAUGEN identifies groundbreaking innovations worldwide whose true value the market has yet to see

NAUGEN, a global innovation accelerator, incubates and scales

Novel · **A**dvanced · **U**nprecedented

Products and technologies across life sciences and deep tech

🚀 **Open Call for Global Innovators: Fast-Track Your U.S. Expansion with NISA 2025-2026**

Are you a global innovator in Biotech, Medtech, or Deep Tech looking to scale in the U.S.?

Led by Naugen in partnership with George Mason University and supported by the Commonwealth of Virginia, **NISA (Northern Virginia International Soft Landing Accelerator)** helps global innovators enter the U.S. market, secure investment, and scale within Northern Virginia's rapidly growing Innovation District in Prince William County, VA.

Naugen brings deep international experience and strategic insight to every cohort, guiding founders through the complexities of the U.S. business landscape. Combined with GMU's research capabilities, NISA is a premier opportunity for startups in Life Sciences, AI, Quantum Computing, Robotics, and Aerospace. We strongly welcome companies developing NAU (Novel, Advanced, Unprecedented) technologies or demonstrating strong interdisciplinary convergence.

💡 **NISA 2025-2026 Program Overview**

1 Phase I: Coaching & Strategy
- Refinement of U.S. market entry strategy and pitch development
- Multi-round pitch sessions to advance into Phase II

2 Phase II: Landing & Growth
- Support for U.S. entity setup and operational structure
- Up to six months of office or laboratory space
- Warm introductions to venture capital, angel investors, and corporate partners
- Collaboration opportunities with George Mason University researchers and regional partners

Join NISA Now

Meet NAUGEN at RESI JPM

Meet us at **RESI JPM NAUGEN Global Innovation Showcase**

Monday, January 12, 1:00 - 1:50pm
NAUGEN: Introducing the Global Innovation Accelerator and its Portfolio & Pipeline Company Showcase

By leveraging its strategy and business development expertise alongside deep scientific and technological insight, NAUGEN cultivates high-potential innovations and companies, accelerating their path toward becoming globally competitive and unlocking exponential value.

MEDMARC®
LIFE SCIENCES INSURANCE

Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: MedTechLifeSci@medmarc.com
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

LEARN MORE
medmarc.com

ISRAEL EXPORT INSTITUTE

Ministry of Economy and Industry
Foreign Trade Administration

ISRAELI COMPANIES PITCHING SESSION

The Israel Health and Life Sciences **ecosystem** comprises more than 1,800 healthtech, medtech, and biotech companies and organizations, forming a global **innovation** powerhouse that combines cutting-edge science with real-world clinical expertise.

The **Israel Export Institute** is a non-profit organization, which supports Israeli companies in connecting and expanding globally.

January 13th | 11:00-12:00 Pitcing Session @ RESI

Participating Companies

Alma THERAPEUTICS

CanopY Immuno-therapeutics

CoPilotMD

HOPEC Bringing Hope to Bladder Cancer

NewPhase

SurgiAI Guiding Every Surgical Step

Contact the Health & Life Science team : https://export.gov.il/en/industry/health/

Or email Director of Health & Life Science, Karin Mor: karinkm@export.gov.il

RESI CONFERENCE REDEFINING EVERY STAGE OF INVESTMENT SEED TO EXIT

NOVOTECH™

Biotech's Partner at Every Phase

Biotech moves fast. Your CRO partner should too.

Phase 1 and early clinical development, built for speed and Proof of Concept.
Meet Novotech at RESI to discuss rapid first-in-human strategies, smarter regional planning, and predictable execution across Australia, China, and key global regions.

Early phase scale you can validate
2,800 Phase 1 trials across APAC, North America, and Europe.

Connect with us on RESI Partnering

SPONSORS & EXHIBITORS

TITLE SPONSORS

brisbane australia

Enterprise Singapore

BioMeta Advancing your discovery

GOLD SPONSORS

KBIC KOBE Biomedical Innovation Cluster

o2h discovery

one nucleus

HiRO

MEDMARC LIFE SCIENCES INSURANCE

NOVOTECH Biotech's Partner at Every Phase

ISRAEL EXPORT INSTITUTE

NAUGEN

apexBrasil

Queensland Government TIQ TRADE + INVESTMENT QUEENSLAND

SILVER SPONSORS

TRILLIUMBIO

CATALYZE Accelerating Translation

BRONZE SPONSOR

POLSINELLI What a law firm *should* be.™

EXHIBITORS

THE MEDTECH CONFERENCE OCT 18-21 | BOSTON, MA Hosted by AdvaMed The Medtech Association

OPIS A Science Driven Biotech Focused CRO

DASH

BIOTECH GATE BUSINESS DEVELOPMENT DATABASE

VENTURE VALUATION

inertia

SPONSORS & EXHIBITORS

brisbane australia

Table #23

Brisbane Economic Development Agency (BEDA) drives the sustainable economic growth of the city. As Brisbane's champion - BEDA works with government and private sector organisations to support global investors to leverage economic opportunities within Brisbane. BEDA drives investment demand for the city in domestic and international markets, showcasing a city that is alive with opportunity and supporting potential investors and businesses with full market entry and expansion strategies. Brisbane is home to world-class innovation and economic opportunities, with key industries such as health, tourism, property and construction, logistics, advanced manufacturing, and business services. As a leader in medical innovation, Brisbane's health sector is a major contributor to the city's economic growth. The sector is on a strong growth trajectory, with healthcare being the city's largest employer. Brisbane's MedTech industry is thriving, driven by cutting-edge research institutes, universities, and world-class talent.

Enterprise Singapore

Table #8

Enterprise Singapore is the government agency championing enterprise development. We are a statutory board operating under the Ministry of Trade and Industry (MTI) of the Singapore government. With a global network in over 35 locations around the world, we drive Singapore companies' global expansion while connecting international businesses to trusted partners in Singapore. Singapore is a powerhouse of growth. As a global hub for trade and innovation, we offer access to a thriving ecosystem of global enterprises, startups, and investors. Known for their commitment to quality and innovation, Singapore companies are also ideal partners for growth. Enterprise Singapore is here for wherever you're growing.
Visit www.enterprisesg.gov.sg for more information.

BioMetas
Advancing your discovery

Table #9

BioMetas: Supporting the Next Generation of Therapeutic Startups
BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.

KBIC
KOBE Biomedical Innovation Cluster

Table #27

The Kobe Biomedical Innovation Cluster (KBIC) is the largest biomedical cluster in Japan, offering a highly integrated platform that promotes networking and innovative collaboration among businesses, academic institutions, and medical organizations. KBIC brings together a concentrated community of nearly 350 companies, universities, research institutes, and specialized hospitals, all dedicated to advancing cutting-edge medical technologies and pioneering scientific discoveries through close collaboration. FBRI is also home to the Foundation for Biomedical Research and Innovation at Kobe (FBRI), the core organization supporting this cluster. KBIC actively promotes biomedical innovation through advanced clinical research and translational medicine, with a particular focus on biomanufacturing as well as cell and gene–based technologies. In addition, KBIC fosters cross-border collaboration and open innovation among cutting-edge startups through its international networks.KBIC provides an ideal environment for organizations seeking to establish a presence in Japan, invest in life sciences, or identify strategic partners across academia, healthcare, and industry.

SPONSORS & EXHIBITORS

MEDMARC® LIFE SCIENCES INSURANCE

Table #14

Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan. (703) 652-1360

one nucleus™

Table #2

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

o2h discovery

Table #10

o2h discovery is a premier provider of small molecule focused drug discovery services, featuring both biology and chemistry capabilities. o2h can support all the stages of early drug discovery, from biological target validation to hit finding, hit expansion, hit to lead, lead optimization and pre-clinical scale-up. o2h operates from its state-of-the-art research centres in Cambridge, UK and Ahmedabad, India. o2h Discovery is part of the o2h group of companies (o2h) founded in 2003 and employs over 500 staff across different departments (chemistry, biology and ADME). Our Indian base allows us to provide an excellent speed and value compared to companies with operations in the West while our UK base provides experienced medicinal chemistry support and sophisticated cellular biology services. o2h's business (people, process and infrastructure) has been built and developed to provide a tier one option for managing discovery collaborations.

HiRO

Table #6

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.

SPONSORS & EXHIBITORS

ISRAEL EXPORT INSTITUTE

Table #7

The Israel Export and International Cooperation Institute (IEICI) was established in 1958 as a non-profit organization by the government of Israel and the private sector. IEICI promotes Israeli goods and services exports, and trade relations, cooperation and strategic alliances with overseas companies. IEICI provides services to thousands of Israeli exporters. IEICI promotes exports through initiatives and programs in many countries, operating through Israeli commercial and economic attachés, as well as local business development representatives. IEICI maintains working relations with foreign diplomats and commercial attachés in Israel and trade organizations throughout the world. It provides information and consulting services, offering extensive connections and assistance in promoting exports of Israeli companies as well as complementary services for the international business community. IEICI initiates and organizes incoming and outgoing commercial delegations and mounts national pavilions and information centers at international exhibitions and conventions throughout the world. IEICI operates through two business development divisions, a technology industries division and a consumer goods division, plus professional services units.

NOVOTECH™
Biotech's Partner at Every Phase

Table #17

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years. For more information or to speak to an expert team member visit www.Novotech-CRO.com

NAUGEN

Table #22

NAUGEN (www.naugen.com) is a global innovation accelerator focused on identifying and advancing groundbreaking technologies and products across life sciences and deep tech. NAUGEN incubates Novel, Advanced, and Unprecedented (NAU) innovations and supports founders in scaling their solutions to global markets. By leveraging its strategy and business development expertise alongside deep scientific and technological insight, NAUGEN cultivates undiscovered high-potential innovators worldwide and accelerates their path toward becoming globally competitive companies.

apexBrasil

Table #3

The Brazilian Trade and Investment Promotion Agency (ApexBrasil) works to promote Brazilian products and services abroad and attract foreign investments to strategic sectors of the Brazilian economy. To achieve its goals, ApexBrasil carries out several trade promotion initiatives aimed at promoting Brazilian products and services abroad, such as prospective and trade missions, business rounds, support to the participation of Brazilian companies in major international fairs, visits of foreign buyers and opinion makers to learn about the Brazilian productive structure, among other business platforms that also aim at strengthening the Brazil brand.

Queensland Government
TIQ TRADE + INVESTMENT QUEENSLAND

Table #21

Trade and Investment Queensland is the Queensland Government's dedicated global business agency for international investment and trade. Our global teams are based in 27 locations across 18 international markets, and eight regional Queensland locations. We connect Queensland to the world and the world to Queensland, driving global business opportunities.

SPONSORS & EXHIBITORS

CATALYZE
Accelerating Translation

Table #13

The NHLBI Catalyze Program is designed to accelerate the transition of basic scientific discoveries into viable therapeutics, devices, and enabling technologies that address heart, lung, blood, and sleep (HLBS) diseases and disorders. The Catalyze Coordinating Center (RTI) provides a coordinated suite of support, including funding, milestone-driven project management, technical, regulatory and commercialization services to US-based universities, non-profits, and small business. Product definition funding opportunities, preclinical and regulatory services are available to help navigate translational development challenges. Through its structured continuum of support, Catalyze bridges the gap from early discovery to first-in-human testing across the HLBS research spectrum.

TRILLIUMBiO

Table #16

TrilliumBiO is a biomarker discovery company specializing in the development and commercialization of novel diagnostic tests to translate scientific discoveries into real-world clinical impact. The company has launched over 100 assays, collaborates with partners domestically and internationally, and processes over 500,000 samples annually through a multi-accredited, CLIA-certified laboratory. Headquartered in Maryland, just outside Washington, D.C., TrilliumBiO operates within the nation's third-largest biopharma hub. The company's multidisciplinary leadership team brings decades of experience delivering value to patients and partners. TrilliumBiO is your partner from discovery to delivery, working together through R&D, regulatory milestones, and clinical use translating innovation into impact.

POLSINELLI
What a law firm *should* be.™

Table #18

Polsinelli is an Am Law 100 firm with more than 1,200 attorneys in over 25 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on life sciences, health care, real estate, finance, technology, and private equity.

SPONSORS & EXHIBITORS

THE MEDTECH CONFERENCE
OCT 18-21 | BOSTON, MA
AdvaMed

Table #1

Join us October 18–21, 2026, in Boston, MA for The MedTech Conference, hosted by AdvaMed. This is where the medtech community gathers in one place to explore the latest in innovation, investment insights, regulatory and payment updates, AI, and the future of health care technology. Connect with 4,000+ leaders from global medtech companies, fast-growing startups, investors, and strategic partners. With curated partnering, dynamic education, interactive innovation spaces, and high-value networking, The MedTech Conference is where the industry comes together to accelerate what's next.

OPIS
A Science Driven Biotech Focused CRO

Table #15

OPIS, founded in 1998 by physicians from the pharmaceutical industry, is a global full-service CRO with 26 years of experience. The company provides end-to-end clinical trial support across Phase I–IV studies, including interventional, non-interventional, and medical device trials, as well as pre- and post-marketing studies for medical and diagnostic devices, nutraceuticals, and food supplements. With a dedicated team that has managed more than 1,500 studies, OPIS offers expertise in trial design, medical writing, statistics, and high-quality global execution across a broad range of therapeutic areas. OPIS operates through affiliates in 18 countries worldwide.

BIOTECH GATE
BUSINESS DEVELOPMENT DATABASE
VENTURE VALUATION

Table #20

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

inertia

Table #19

Inertia is a trusted partner for startups and innovators looking to bring bold product ideas to life. We support clients through every stage of hardware development—from concept to manufacturing—offering expertise in design, prototyping, engineering, and supply chain management. Beyond the creative spark, we handle the critical details that ensure success, like design for manufacturing and logistics. For us, innovation begins with a blank page and the belief that 'nothingness' can become something impactful. We're inspired by the genius of our clients and team, driven to turn visionary ideas into real-world solutions. With curiosity as our compass and execution as our strength, Inertia is committed to building not just what's new, but what's needed—solutions that make life easier, better, and more joyful. With the right vision, we know we can go anywhere.

DASH

Table #12

Dash Bio is a different kind of bioanalytical CRO. Traditional bioanalysis is slow, manual and error prone. Dash changes the equation as the only tech-first bioanalysis partner, putting both speed and quality at the forefront. Processing every sample on an automated platform, they eliminate variability and delays, delivering high quality, GLP-compliant results for preclinical and clinical studies in days, not months. Dash currently provides ELISA, MSD, LC MS and qPCR assays across a wide range of biomatrices, sample prep methods and customization options, enabling sponsors to move from insight to action, faster. Co-founded by industry veterans on a mission to accelerate drug development, Dash's model publishes pricing upfront with guaranteed results.

RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION

LIFE SCIENCE NATION
Connecting Products, Services & Capital

Table #4,5

Life Science Nation (LSN)

Life Science Nation has built a global partnering backbone that links early stage healthcare companies with capital investors and licensing partners. Our resources combine data, technology, education, and curated events to help innovators prepare for and execute global fundraising and partnering campaigns.

Key Resources

- GPC Platform + RESI Conference Series: Match with investors and partners by product, stage, and allocation needs across Drugs, Devices, Diagnostics, and Digital Health.
- Partner Network: Includes service providers, tech hubs, and agencies that power early-stage life sciences.
- Three Components: Investor & Licensing Partner Database integrated with Salesforce CRM, RESI Partnering Events, and Entrepreneurial Education.

GPC *Global Partnering Campaign*

Global Partnering Campaign (GPC)

The GPC combines LSN's investor/licensing database with Salesforce CRM. Subscribers receive a vetted Global Target List (GTL) of likely partners organized into priority tiers:

- Tier 1: Exact mandate fit
- Tier 2: Opportunistic investors seeking compelling assets
- Tier 3: Potential fits based on recent activity

Profiles update daily and integrate with CRM to track outreach, materials shared, notes, and investor pipeline reporting.

LSN BD ASSIST

LSN BD Assist

BD Assist is LSN's managed global outreach program. We build and refine your global target list, integrate it into Salesforce CRM, develop messaging, launch coordinated outreach, and manage meeting scheduling. This enables founders to focus on development while we manage the time consuming work of investor engagement.

What BD Assist Delivers

- AI-optimized messaging for outreach
- Prioritized partner targeting
- Coordinated outreach campaigns
- Confirmed investor meetings synced to your CRM

With over a decade of experience teaching startups how to craft their story and secure funding, LSN combines trusted methodology with hands-on execution. Results speak for themselves: 90% of companies in our Australian accelerator cohort secured funding or partnerships.

If you're raising capital or licensing in the next 12 months, BD Assist is your turnkey solution for launching a global campaign without building an in-house BD team.

Contact us at salescore@lifesciencenation.com to get started.

LIFE SCIENCE NATION PUBLICATIONS

LSN Publications

LSN publishes educational content and market insights to support early stage companies as they prepare for global fundraising. These publications highlight investor trends, partnering strategies, and best practices for telling a clear and compelling story.

NEXT PHASE»



JANUARY 12 - INVESTOR PANELS

Location: Golden Gate C1

9 AM | "FIRST CHECK" VCS

Backing Founders at the Very Beginning

Securing the first institutional check is often the toughest step for health and life science founders. This panel features pre-seed and seed investors discussing how they assess founders, key early milestones, and how they support companies toward the next round. Learn what convinces first-check VCs to back a vision.

10 AM | MEDTECH STRATEGICS

Driving Growth Through Strategic Partnerships and Acquisitions

Strategic investors from major medtech companies offer capital, expertise, networks, and potential acquisition paths. This panel will feature executives discussing how they assess emerging technologies, decide when to partner or acquire, and what startups should know to align with corporate priorities and speed successful commercialization.

Enterprise Singapore 11 AM | ASIA CROSS BORDER INVESTMENTS

Interest is rising in biomedical technologies and therapies from Asia addressing global healthcare needs. This panel explores how cross border capital, talent, and technologies drive advances in precision medicine, innovative therapies, and next generation diagnostics, and how partnerships with regions like Singapore shape global healthcare innovation and commercialization.

1 PM | FAMILY OFFICES

Patient Capital with a Personalized Approach

Family offices provide flexible, long-term, mission driven capital for healthcare innovators. This panel features investors discussing how they evaluate opportunities, why they invest in healthcare, and how they partner with entrepreneurs, including diversification, alignment with family values, and co-investment approaches shaping the sector.

2 PM | CELL & GENE THERAPY

Investing in the Next Frontier of Medicine

Cell and gene therapies are transforming medicine with the potential to cure previously untreatable diseases, yet challenges remain in manufacturing, regulation, reimbursement, and scaling. This panel features investors and strategics discussing what excites them, how they assess risks, and where capital is flowing.

3 PM | WHEN SHOULD COMPANIES EXIT STEALTH MODE?

Timing the Transition from Quiet Development to Public Visibility

For early-stage life science and healthcare companies, timing a stealth exit is crucial. This panel features investors, founders, and strategics discussing best practices, aligning communications with fundraising and development, signals investors seek, and strategies to build momentum for maximum impact when entering the spotlight.

4 PM | AGING AND LONGEVITY

Investing in Solutions for the World's Aging Population

As populations age, demand grows for innovations that extend healthy lifespans and improve quality of life. This panel features investors and experts discussing emerging science, market opportunities, business models, and how capital is deployed to support longevity solutions addressing critical healthcare challenges.

JANUARY 12 - 9AM | "FIRST CHECK" VCS

Backing Founders at the Very Beginning

For many healthcare and life science entrepreneurs, the hardest capital to secure is the very first institutional check. "First check" venture funds specialize in identifying promising teams and ideas before they are fully validated, taking on the highest risk to catalyze innovation.

This panel will bring together early-stage VCs who focus on pre-seed and seed investing. Panelists will share how they evaluate founders, what milestones matter most at this stage, and how they support portfolio companies in reaching the next round of financing. Learn what it takes to convince a first-check investor to bet on your vision.

Kenny Nova, Member, Mid Atlantic Bio Angels (Moderator)

Kenny Nova is an investor, serial entrepreneur and advisor of early-stage companies. He is focused on identifying, funding and commercializing life science and technology innovation. He is a Board Advisor for the Tufts Entrepreneurship Center, member of the Tufts University President's Council, member of the New York Angels and the Mid Atlantic Bio Angels. He received his BA from Tufts University, MBA from the Kellogg School of Management at Northwestern University and studied at the Biodesign program at Stanford University.

Jeff Chu, Managing Partner, Features Capital

Jeff has over 20 years of experience as a researcher, inventor, entrepreneur, advisor, and investor. Currently, he is the co-founder and Managing Partner of Features Capital, a venture fund specializing in early-stage MedTech innovations that accelerate the future of healthcare. Before this, he helped build, scale, and exit a leading product development and commercialization company where he helped commercialize innovations from MedTech startups to multi-nationals. Jeff holds over 16 patents, has served as Principal Investigator for numerous NIH and DoD federally funded research grants, and is an Entrepreneur-In-Residence at both Northeastern University's The Roux Institute and Dartmouth College's Magnuson Center for Entrepreneurship.

Mahesh Narayanan, Managing Partner, Neuvation Ventures

Mahesh Narayanan is a founder, investor, and accelerator director with 15+ years of leadership in biotechnology, life sciences, and technology ventures. As Managing Partner of Neuvation Ventures, he leads early-stage investments in Brain Health, medical devices, and digital health. He co-founded MatchPlay Group, supporting founders with diligence, capital readiness, and investor connections. Having founded and scaled multiple companies with two successful exits, Mahesh leverages his entrepreneurial experience to guide startups from concept to commercialization. A mentor to 100+ global startups, he is dedicated to fostering DeepTech and healthcare innovation, building ecosystems where science, technology, and venture capital converge for human health impact.

Jessica Owens, General Partner, INITIATE Ventures

Jessica Owens is a Founding General Partner at Initiate Ventures, where she funds and co-founds transformative companies at the intersection of life sciences, healthcare, and technology. Jessica is an experienced venture investor, serial entrepreneur, and scientist. She has been part of the founding team of seven start-ups, including GRAIL, where she led various business & commercial functions before the company's $8B acquisition. She was also an investor at Kleiner Perkins. Today, Jessica applies her experience to support early-stage startups that possess the potential to improve millions of lives. She is a Kauffman Fellow. She earned her MBA from Harvard Business School, an MS in Cancer Biology from Stanford University, and her bachelor's degree from Agnes Scott College, where she served on the Board of Trustees.

James Spann, Founder & Managing Partner, Boyd Street Ventures

James, a University of Oklahoma graduate on a Navy ROTC scholarship, served six years as a Marine captain before a 30-year corporate career in life sciences, including leadership roles at GlideNet Healthcare, Simpler Healthcare (IBM Watson Health), Aramark Healthcare Technologies, AmerisourceBergen, and Medline Industries. Since 2005, he observed OU-affiliated startups struggle to secure venture capital and, with Jeff Moore, founded Boyd Street Ventures in Norman, Oklahoma in 2021. James holds a B.A. in Marketing from OU, an M.B.A. from Indiana Wesleyan University, and executive program certificates from Kellogg and Wharton, dedicating his efforts to fostering entrepreneurial growth.

Varun Turlapati, Managing Director, Chaanakya Capital

Varun holds a Master's degree in Electrical and Computer Engineering and brings nearly two decades of experience across the technology industry. He has worked with organizations ranging from early-stage startups to established enterprises, gaining a strategic understanding of how transformative technologies scale—through both successes and failures. Varun serves on the board of a nonprofit venture organization and has consulted with MedTech startups alongside Dr. Vega Leonel. In venture capital, he has served as a Venture Analyst and Venture Partner, backing innovative founders. As a former Fractional CTO at a PropTech startup, he offers hands-on insight into scaling deep tech. Beyond technology, Varun pursues regenerative farming and operates two small businesses, reflecting his commitment to sustainable impact.

JANUARY 12 - 10AM | MEDTECH STRATEGICS

Driving Growth Through Strategic Partnerships and Acquisitions

Strategic investors from leading medtech companies play a critical role in advancing healthcare technologies. Beyond capital, they provide market knowledge, distribution networks, regulatory expertise, and the potential for acquisition. For startups, securing strategic alignment with medtech leaders can be transformational.

In this 50-minute panel, executives and investment leaders from medtech strategics will discuss how they evaluate emerging technologies, when they choose to partner or acquire, and what innovators should know about aligning with corporate priorities. Gain insights into how strategic capital differs from venture investment and how it can accelerate commercialization.

Rod Cotton, Venture Partner, 2Flo Ventures (Moderator)

Rodney Cotton is an entrepreneurial leader in the pharmaceutical and biotech industry known for his holistic perspective, bias for action, and commitment to agile execution. He serves as an independent director for Orchard Software and Moleculera Labs, and as an advisor to General Genomics and 2Flo Ventures. Previously, Rod spent more than two decades at Roche, culminating as SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO of Roche Diagnostics North America. He led major enterprise initiatives, large-scale transformations, and COVID-era diagnostic accelerations. A recognized voice on health equity, Rod has received multiple national honors and holds graduate degrees in business and strategy.

Jian Cao, Sr Research Manager and Technical Fellow, Medtronic

Program Director and Technical Fellow at Medtronic, with over 25 years of experience advancing implantable cardiac medical devices and algorithms—including pacemakers, defibrillators, and insertable cardiac monitors. He has successfully led projects from initial concept through human clinical studies to global commercialization. In recent years, Jian has managed programs across international R&D centers to develop and launch new conduction system pacing technologies worldwide, driving double-digit growth. Jian holds a Ph.D. in Bioengineering from Penn State University, where he was recognized as an Outstanding Engineering Alumni, and an Advanced Certificate for Executives from the MIT Sloan School of Management. An accomplished innovator, he holds more than 75 issued U.S. patents and received the Medtronic Patent of Distinction Award in 2019. For the past three years, Jian has served as a Judge for the RESI JPMorgan Innovator's Pitch Challenge.

Jessica Tam, Associate Director, Baxter Healthcare

Jessica Tam's passions lie at the intersection of technology and healthcare with a track record of developing and commercializing new innovations. She is currently an Associate Director at Baxter Healthcare focused on business development and M&A with experience across product marketing, corporate strategy, business development, R&D, and manufacturing. Jessica received a BS in Chemical Engineering for Stanford University and an MBA from the University of Chicago Booth School of Business.

Sponsored by

Enterprise Singapore

JANUARY 12 - 11AM | ASIA CROSS BORDER INVESTMENTS

There is growing interest in innovative biomedical technologies and therapies emerging from Asia to tackle global healthcare challenges and needs. Investors, corporates, startups and healthcare systems recognise the imperative to bridge between the East and West to maximise the impact on healthcare outcomes and deliver value-based care within and beyond hospital settings.

This panel will unpack how cross-border capital, talent and technologies are converging to accelerate breakthroughs in precision medicine, innovative therapies, and next generation diagnostics, and how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.

Irene Cheong, Assistant Chief Executive, Innovation & Enterprise, A*STAR (Moderator)

Ms Irene Cheong is the Assistant Chief Executive, Innovation & Enterprise (I&E), at A*STAR. She provides operational leadership to the I&E Group and National Platforms and drives I&E's daily operations. She also leads A*STAR's industry engagements, catalysing more impactful A*STAR spin-offs and growing significant value in A*STAR's existing start-up portfolio. Since joining A*STAR, Ms Cheong has led productisation and alignment efforts in MedTech, while putting in place strong programmes and partnerships to jumpstart A*STAR's venture building and spin-off capabilities. As Acting CEO, DxD Hub, Ms Cheong also oversees numerous collaborations with clinicians, scientists and companies to co-develop medically regulated diagnostics from early-stage biomarker validation through validation into regulatory and manufacturing. Ms Cheong holds core capabilities in biotech, medtech and diagnostics domains as well as industry development and venture creation.

Lee Chuan Teck, Chairman, Enterprise Singapore

Mr Lee Chuan Teck is the Executive Chairman of Enterprise Singapore. Enterprise Singapore is the government agency championing enterprise development. The agency works with committed companies to build capabilities, innovate and internationalise. It also supports the growth of Singapore as a hub for global trading and startups, and builds trust in Singapore's products and services through quality and standards. Previously Enterprise Singapore's Chief Executive Officer, Chuan Teck was appointed as Executive Chairman on 1 April 2024. Prior to this, Chuan Teck was Permanent Secretary (Development) of the Ministry of Trade and Industry from June 2018 to April 2023 where he was responsible for the development of Singapore enterprises, and oversaw the tourism and energy sectors, as well as competition and consumer protection issues. On the trade front, he focused on expanding economic connectivity and strengthening bilateral economic relationships with Southeast, South and Central Asia and Latin America.

Ansbert Gadicke, Managing Partner, MPM BioImpact

Dr. Ansbert Gadicke is the Managing Partner of MPM BioImpact. Ansbert founded MPM Capital in 1992 as a biotech venture capital firm and later its affiliate BioImpact Capital for private/public funds. He is the driving force at MPM BioImpact behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), ElevateBio, Orna Therapeutics and ReNAgade Therapeutics (acquired by Orna). Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University

Nirdesh Gupta, Managing Partner, Cedars-Sinai Technology Ventures

Dr. Nirdesh K. Gupta, PhD, is the Managing Partner of Cedars-Sinai Technology Ventures and the Cedars-Sinai Accelerator, where he leads key operations for business units such as 3rd Street Technologies, The Medically Associated Science and Technology (MAST) & Cedars-Sinai Biomanufacturing Center (CBC). Dr. Gupta directed CSTV's Seed Fund and Equity investments and have $275M+ equity under management representing over 20 companies, with multiple significant financial exits. Dr. Gupta's leadership has led to multiple successful partnerships with industry, and he has directly played an instrumental role in company co-creation of several Cedars-Sinai spinoffs notably Prometheus Biosciences, Gemelli Biotech, and Gravidas Diagnostics. He has also served on the UNESCAP Business Advisory Council and Innovation Task Force. Dr. Gupta holds a bachelor's and a PhD in pharmaceutical sciences.

Sharon Chan, Vice President, Johnson & Johnson Innovation - JLABS Asia Pacific

Sharon is a passionate and respected global health leader with extensive experience in business and product development across pharmaceuticals, medical devices, vaccines and technology platforms. As VP JLABS Asia Pacific, Sharon is responsible for setting and driving the long-term growth strategy and plan for JLABS in the region, which includes JLABS Singapore and JLABS @ Shanghai. Supported by a strong commitment to Credo-based leadership, Sharon is a trusted business strategist and collaborator, known for driving innovation strategy with a focus on agility and a caring mindset. She manages the portfolio of JLABS, collaborates with internal and external business partners across multiple sectors, and drives high-quality company sourcing from innovation hotspots across Asia Pacific.

JANUARY 12 - 1PM | FAMILY OFFICES

Patient Capital with a Personalized Approach

Family offices bring flexibility, long-term thinking, and mission-driven investment strategies to healthcare innovation. Often investing outside traditional venture models, they can provide patient capital and unique networks of support for early- and growth-stage companies.

This panel will feature family office investors sharing how they evaluate healthcare opportunities, their motivations for investing in the sector, and how they work with entrepreneurs. Discussion will include portfolio diversification, alignment with family values, and co-investment opportunities. Hear how family offices are shaping the healthcare landscape with a distinctive investment style.

Brianna McDonald, CEO, Ecosystem Venture Group (Moderator)

Brianna McDonald been investing in early-stage innovation since 2005, turning curiosity into a commitment to help founders and reshape how venture capital serves them. She cares deeply about people and the problems they're solving, and brings her time, expertise, and capital to support them. Grounded in grit, she doesn't shy away from hard conversations; she believes in transparency, fairness, and accountability create better companies and a healthier ecosystem. As an investor, she focuses on clear paths to profitability, fair deal terms, and strong governance that protects both founders and investors. Through Keiretsu Forum Northwest & Rockies, Ecosystem Venture Group, and NW Angel Fund, she works to direct capital, education, and community into diverse early-stage companies that can improve the world.

Andrew Krowne, Managing Director, Dolby Family Ventures

Andrew joined Dolby Family Ventures in 2014 and is now Managing Director, leading technology investments across diverse portfolios. He serves as a board director of Coformer.AI and board observer at CaliCat and SoilAction, with previous board roles including Discover Echo, PhaseFour, Roviero, DiamondAge, Plethora, and TripleBlind. A Kauffman Fellow (Class 22), Andrew previously worked in investment banking at Barclays, Merrill Lynch, and RBS across Technology, Media & Telecom, Aerospace & Defense, and Pharmaceuticals. He holds an MBA with honors from UC Berkeley Haas School of Business and a B.S. in Finance and Accounting from the University of Virginia.

Ken Lin, CEO & Co-Founder, ABIES Capital

Ken Lin is the CEO and Co-founder of ABIES Capital, a firm focused on innovative healthcare startups and investments. He brings extensive experience in global asset allocation, fundraising, brand building, and healthcare enterprise management. ABIES Capital pursues a dual strategy, managing healthcare venture capital assets through a Fund of Funds approach with leading U.S. VC firms, while also making direct investments in high-potential biotech, medtech, and health tech companies. Previously, Ken spent over a decade in the medical device industry, holding management roles at Medtronic and Biotronik in Taiwan. He holds advanced degrees from National Taiwan University and multiple professional certifications.

Michael Loftus, Director, PoC Capital

Michael Loftus, Director at PoC Capital, is a highly connected and accomplished executive in biotech financing and clinical trials. Renowned for his strategic vision, extensive industry network, and proven ability to execute complex transactions, Michael is a trusted partner for early- to mid-stage biotech companies seeking capital-efficient solutions for clinical trials. At PoC Capital, Michael leads efforts to fund public microcap biotechs listed on NASDAQ or NYSE, with market capitalizations ranging from $10 million to $200 million. The firm specializes in supporting Phase Ib, IIa, or similarly sized clinical trials, with average deal sizes between $2 million and $6 million.

Steven Saltzstein, CEO, FORCE Family Office

Steven Saltzstein has been in the family office space since 1994 where he sourced, structured, negotiated and closed over a $1B in investments. In the past 12 months Mr. Saltzstein has invested in e-sports, A.I., real estate, medical devices, cannabis and mining. Prior to founding FORCE Family Office, Mr. Saltzstein founded Family Office Networks and has built the largest network of investment-seeking family offices in the U.S. Since 2012, Mr. Saltzstein has made over $1.7B in co-investment introductions to Family Offices. Mr. Saltzstein is an experienced partner with a demonstrated history of working in the financial services industry. Skilled in corporate development, capital raising, mergers & acquisitions, start-ups, marketing, and corporate finance Mr. Saltzstein prides himself on being a generalist and has orchestrated investments in healthcare, (medical device, biotech, Pharma and therapeutics), technology, social media, precious metals, oil and gas, alternative energy, crypto currency and other sectors.

JANUARY 12 - 2PM | CELL & GENE THERAPY

Investing in the Next Frontier of Medicine

Cell and gene therapies represent one of the most transformative areas of modern medicine, offering the potential to cure diseases once thought untreatable. Yet challenges remain around manufacturing, regulation, reimbursement, and scaling therapies to broader patient populations.

This panel convenes investors and strategics at the forefront of the cell and gene therapy revolution. Panelists will share what excites them in this space, how they assess technical and commercial risk, and the types of partnerships that can accelerate progress. Explore where capital is flowing in this rapidly advancing frontier.

Karen Chu, CEO, Harvest Integrated Research Organization (HiRO) (Moderator)

Karen Chu is the CEO of Harvest Integrated Research Organization (HiRO) with more than 20 years of international CRO management and operational experience. A leading global executive in the industry, she has overseen 600–800 clinical trials annually and led a worldwide clinical organization of more than 5,700 professionals across 55 countries. Karen brings deep expertise in cross-regional mergers, personnel leadership, and business development. She has also conducted due diligence for biotech and medical device companies and serves as a board member of a global biotech company.

Robert Balfour, Principal, ALSA Ventures

Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate startup entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.

Bettina Ernst, Director, BERNINA BioInvest

Bettina has over 8 years of experience investing in healthcare companies and serves on the boards of several early-stage Swiss biotech firms, the Swiss Biotech Association, and advisory boards for the Swiss Entrepreneur Fund and Innosuisse's Innovation Council. She co-founded two biotech companies and previously spent 10 years in fundamental immunology research in the US (Scripps Research Institute) and Europe. Bettina holds a PhD in immunology and a degree in natural sciences from ETH Zurich, and she is based in Switzerland, combining scientific expertise with investment and entrepreneurial leadership in the life sciences sector.

Maite Malet, Principal, Asabys Partners

Maite is a Principal at Asabys, where she joined in 2019 and focuses on sourcing, executing, and managing investments across the firm's healthtech portfolio. She also plays an active role in Asabys' fundraising and corporate development initiatives and currently serves as a board observer for Qida, XRHealth, Medasense, and Deepull. Prior to Asabys, Maite led Business Development at Sphera Global Healthcare and worked at Antai Ventures, supporting the incubation of digital businesses. She began her career at Deloitte Corporate Finance. Maite is pursuing a graduate program in Corporate Innovation and Sustainability at Harvard University and holds degrees in International Business and Digital Marketing.

Ahmed Mousa, Executive, LAFANA

Ahmed Mousa, MD is the Head Business Development at Tamer Group, based in Saudi Arabia. Dr. Mousa is leading the Tamer Life Sciences project with special focus in cell & gene therapy in rare diseases and oncology. Dr. Mousa spent 25 years in the healthcare industry in Egypt, Saudi Arabia, and UAE. He held leading positions in Sanofi and Novartis in the region and in a couple of leading local firms in Saudi Arabia in diagnostics and manufacturing. Dr. Mousa had milestones in leading transformations, promoting integrity and ensuring diversity. His goal is to democratize science through crossing the borders for wider participation in the era of precision medicine.

JANUARY 12 - 3PM | WHEN SHOULD COMPANIES EXIT STEALTH MODE?

Timing the Transition from Quiet Development to Public Visibility

For early-stage life science and healthcare companies, deciding when to exit stealth mode is a pivotal milestone. Revealing too early may attract attention before a company is ready, while waiting too long risks missing key opportunities with investors, partners, or talent.

This 50-minute panel brings together investors, founders, and strategics to discuss best practices for timing a stealth exit. Panelists will explore how to align communications strategy with fundraising and product development, what signals investors look for, and how to build momentum at the right moment. Learn how to position your company for maximum impact when stepping into the spotlight.



Jack Florio, Investor, NuFund Venture Group (Moderator)

Jack Florio is a senior executive with 50+ years of global experience across pharmaceuticals, biotechnology, medical devices, digital health, and digital therapeutics. An active angel investor since 2001 with NuFund Venture Group, he has personally invested in 20+ companies, reviewed hundreds, and led diligence on dozens, focusing on medical devices, therapeutics, and digital health. Jack serves on BIOCOM's Capital Development and Partnering Committee and Medical Device Committee. He holds a BS in Pharmaceutical Sciences from Columbia University, an MBA from NYU Stern, and FINRA Series 7, 63, 79, and 82 licenses.

Rick Berenson, Director - Executive Board, Mass Medical Angels

As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the "wisdom of an expert crowd." He'll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.

Juan Cueva, Senior Director, Search & Evaluation, West North America, Johnson & Johnson Innovation

Juan is Director of Early Innovation Partnering at Johnson & Johnson Innovation, California, focusing on pharmaceutical innovation in neuroscience and product development. He identifies licensing, collaboration, and investment opportunities aligned with Johnson & Johnson's strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders. Previously, he was Investor and Board Observer at Action Potential Venture Capital, leading sourcing and due diligence in bioelectronic therapeutics. Juan has held roles in venture capital, management consulting, and business development at Ultragenyx Pharmaceuticals. He mentors underrepresented STEM students and professionals and serves on the board of the Hispanic Foundation of Silicon Valley.

Dushyant Pathak, Interim CEO, Autobahn Labs

Dushyant is interim CEO at Autobahn Labs with two decades of experience spanning research, business, venture capital, and leadership in academia and industry from Fortune 500 to startups. He has served as a Section 16 SEC-reporting officer, led biotech business development, clinical operations, product development, and oversaw transformative alliances, M&A, and a NASDAQ IPO. Formerly UC Davis's first Associate Vice Chancellor of Research, he founded Venture Catalyst and teaches entrepreneurship and life science innovation at the University of San Francisco. He also advises drug discovery companies through VentureEdge LLC. Dushyant holds a Ph.D. from Northwestern and an MBA from Berkeley Haas.

Jojo Platt, US Partnerships Lead, Corundum Neuroscience

JoJo Platt is US Partnerships Lead at Corundum Neuroscience, focusing on sourcing early-stage neuroscience companies and research. With 15+ years in neurotechnology, she played a key role in launching bioelectronic medicine, its peer-reviewed journal, and the Feinstein Institute's Center for Bioelectronic Medicine. JoJo has built a network of 5,000+ researchers, entrepreneurs, and industry leaders across neuroscience, engineering, data science, and materials science. She partners with startups, academic institutions, and venture firms to accelerate opportunities, travels globally to stay connected, and serves on organizing committees for leading neurotech conferences and summits.

JANUARY 12 - 4PM | AGING AND LONGEVITY

Investing in Solutions for the World's Aging Population

With populations aging worldwide, there is growing demand for innovations that extend healthy lifespans, improve quality of life, and reduce the burden of age-related disease. From therapeutics to digital health platforms, the longevity sector is attracting increasing investor attention.

This panel features investors and experts focused on aging and longevity. Panelists will discuss emerging science, market opportunities, and the business models that can deliver sustainable value. Hear how capital is being deployed to support innovations that address one of the most pressing healthcare challenges of our time.

Gunes Bozkurt, Director of Venture Investments, Beiersdorf

Gunes Bozkurt is a director of Venture Investment at Beiersdorf Corporate Venture Capital. Bozkurt works on private investments and serves on several company boards. Previously, she spent 4+ years at RA Capital investing in biotech companies and identifying compelling opportunities for company creation. Prior to joining RA Capital, she had a long academic career in reputable institutes in Boston, Whitehead Institute and Boston Children's Hospital. Bozkurt holds MSc and PhD degrees in biochemistry from Universität Heidelberg.

Karen Harris, CFO & Head of Mission Related Investments, Alzheimers Drug Discovery Foundation

Karen Harris is Head of Mission-Related Investments and CFO at the Alzheimer's Drug Discovery Foundation (ADDF), where she drives strategic planning, financial growth, and manages venture-based investments. She oversees a diverse portfolio of securities and royalty arrangements with universities and biotech companies, manages banking relationships, and reports to ADDF's Board of Governors. Previously, she was Global COO of UBS's $1B equity capital markets division and a Director at Merrill Lynch. Karen holds an MBA in Finance from Stanford, graduating first in her class, and a BA in Economics from Columbia University.

Uplaksh Kumar, COO, Foresite Capital

Uplaksh is a Venture Partner at Foresite Capital, passionate about improving human health. He was SVP of Strategic Operations at GRAIL, where he launched Galleri to detect multiple cancers early, and previously served as the first Head of Operations at Verily. He has held leadership roles at Life Technologies, BD, LONZA, and Qiagen, and co-founded RoosterBio, a regenerative medicine company. Uplaksh is an experienced business leader with a track record of scaling operations in medical devices, cellular therapy, life sciences, and biopharma globally, and executing financing including private investment and IPOs.

Swati Mehta, Managing Director, 25BIO

Senior finance leader passionate about growing people and businesses. Results oriented & skilled at leading global teams through complex projects from concept to completion. Extensive experience of working with executive teams on business growth and expansion plans, strategy & organizational design. Board member & Leadership team member.

Garth Smith, VP, Business Development & Partnerships, Ontario Brain Institute

Dr. Smith is VP of Business Development and Partnerships at the Ontario Brain Institute, leading commercialization, investment, and global partnership initiatives, including a for-profit spinoff to expand OBI's investment and collaboration activities. He previously led two CNS startups to first-in-human trials, resulting in acquisitions by multinational corporations, and worked as a product development/regulatory consultant and tech transfer officer. Dr. Smith earned a BSc from the University of Toronto, an MSc from UBC, a PhD from Cambridge as a Commonwealth Trust Scholar, and completed a postdoctoral fellowship at the University Health Network in Toronto.

JANUARY 13 - INVESTOR PANELS

Location: Golden Gate C1

9 AM | PARTNERING WITH GLOBAL PHARMA

How Big Pharma Impacts Early Stage Innovation

Global pharmaceutical companies drive life science innovation with resources, pipelines, and commercialization expertise. This panel features pharma executives and corporate investors discussing what they seek in early-stage collaborations, how deals are structured, and insights on building productive partnerships.

10 AM | WOMEN'S HEALTH

Investing in an Underserved Market with Enormous Potential

Women's health has long been underfunded despite significant unmet needs. This panel features investors and entrepreneurs discussing how opportunities are evaluated, progress in closing the investment gap, and emerging breakthroughs, highlighting how capital is being deployed to improve outcomes for women globally.

11 AM | AI IN HEALTHCARE

Redefining R&D and Care Delivery with Artificial Intelligence

Artificial intelligence is transforming healthcare by streamlining drug discovery, accelerating trials, and improving patient care. This panel features investors and experts discussing promising use cases, data and regulatory challenges, and what makes AI-enabled companies sustainable, highlighting AI's impact from lab to patient.

1 PM | ORPHAN & RARE DISEASES

Unlocking Innovation for High-Need, Niche Markets

Orphan and rare diseases affect millions, yet most lack treatments. This panel features investors and strategics discussing how they assess scientific promise, the role of patient advocacy, and challenges in commercializing therapies for small populations, highlighting why rare diseases are an increasing focus for investment.

2 PM | CORPORATE VC

Strategic Investment Beyond the Balance Sheet

Corporate venture capital arms offer startups funding, strategic expertise, industry connections, and commercialization pathways. This panel features CVC leaders discussing how their approach differs from traditional venture funds, balancing financial and strategic goals, the companies they target, and integrating investments into corporate priorities.

3 PM | TECHBIO & SYNTHETIC BIOLOGY

Engineering Biology for the Next Wave of Innovation

The convergence of biology and technology is driving techbio and synthetic biology, enabling programmable biology, new materials, and next-generation therapeutics. This panel features investors and entrepreneurs discussing what excites them, how they evaluate platforms versus products, and where they see long-term opportunities.

4 PM | 2026 OUTLOOK: VC PERSPECTIVES

Where Investors See Healthcare Innovation Headed

After years of volatility, life sciences investment is stabilizing, with U.S. VC funding rising 16% in 2024 and global investment reaching $48.4 billion. This panel features investors discussing market trends, sector momentum, early-stage funding strategies, and what entrepreneurs can expect when raising capital.

JANUARY 13 - 9AM | PARTNERING WITH GLOBAL PHARMA

How Big Pharma Impacts Early Stage Innovation

Global pharmaceutical companies remain central to advancing life science innovation, leveraging their resources, pipelines, and commercialization expertise to bring therapies to market. For startups, partnering with big pharma can validate science, open doors, and accelerate growth.

This panel will feature pharma executives and corporate investors discussing what they look for in early-stage collaborations, how they structure deals, and where they see unmet needs. Gain insider perspectives on how pharma approaches innovation and what it takes to build productive partnerships.

Ekaterine Kortkhonjia, Sr. Director, Early Innovation Partnering, Johnson & Johnson Innovation (Moderator)

Eka is a Senior Director of Early Innovation Partnering at Johnson and Johnson. In this role Eka is responsible for identification, diligence and strategic transactions for data science and oncology opportunities for Johnson and Johnson Innovative Medicines. Eka joined Johnson and Johnson from Genentech/Roche where she spent over 10 years in various roles, including Pharma Partnering, Biomarker Development and Finance. Eka hold a Ph.D. in Chemistry and Chemical Biology and M.S. in Biophysics.

Marc Appel, Managing Partner, Pacific Bridge NY (Moderator)

Marc Appel, JD, MBA, is an advisor to leading university innovation programs, including Yale's Blavatnik Program, Cornell's technology transfer office, and Dartmouth's Cancer Accelerator. He founded Orange Grove Bio and served as CEO from 2019 to 2024, and has helped launch biotech companies such as IpiNovyx Bio and Allonix Therapeutics. Previously, Marc was a healthcare investor at Marathon Asset Management, Highbridge Principal Strategies, and Eaton Vance, and began his career at McKinsey & Co. A frequent speaker at industry and academic forums, he co-authored a Harvard Business School case on Imprimis Pharmaceuticals. Marc holds degrees from Yale, Harvard Law School, and Harvard Business School and is a member of the New York Bar.

Friedemann Janus, SVP, Head of Regional BD & Licensing, Bayer Co.Lab and Divestitures, Bayer

Friedemann Janus, PhD, is Senior Vice President and Head of Business Development & Licensing at Bayer, with 20+ years in pharmaceuticals spanning business development, licensing, strategy, commercial operations, and consulting. He leads Bayer Co.Lab, a global incubator network, develops regional strategies connecting to local innovation ecosystems, and oversees out-licensing and divestiture activities. Previously, he launched Xarelto's chronic indications as VP & Global Head of Commercial, and was a Partner at McKinsey & Company. Dr. Janus holds a PhD in Molecular Biology from Hamburg University and leverages his scientific expertise to drive innovative healthcare solutions globally.

JANUARY 13 - 10AM | WOMEN'S HEALTH

Investing in an Underserved Market with Enormous Potential

Women's health has historically been underfunded, despite representing half the population and vast unmet medical needs. Today, investors are increasingly recognizing opportunities in areas such as reproductive health, maternal care, menopause, oncology, and chronic disease prevention.

This 50-minute panel brings together investors and entrepreneurs advancing innovation in women's health. Panelists will explore how they evaluate opportunities, what progress has been made in closing the investment gap, and where the next wave of breakthroughs is emerging. Learn how capital is being deployed to transform outcomes for women worldwide.

Ralph Morales III, Venture Partner / Executive-in-Residence, Aquillius Ventures (Moderator)

Ralph Morales III is a strategic innovator and commercialization expert in medical devices, AI, and predictive health, with 15+ years of experience developing wearable technologies and machine learning tools for early detection, chronic condition management, and behavioral health optimization. He led healthcare partnerships and AI strategy at Oura, scaling biometric insights into clinical outcomes. Ralph advises medtech firms, startups, and innovation hubs on AI-powered diagnostics, personalized health, and biotech infrastructure, bridging devices, data, and decisions to accelerate breakthroughs in human health.

Yinghong Gao, Venture Partner, Viva BioInnovator

Yinghong Gao is a Venture Partner of Viva BioInnovator. She is responsible for the post investment management of multiple VBI portfolio companies. She is also heavily involved in deal sourcing and spearheading collaborations with external institutions and investment communities in the innovative drug discovery space. Prior to that she has extensive drug R&D and BD/licensing experience working with Neurocrine Biosciences, Arena Pharmaceticals, Merck KGaA and other biotech companies. She has contributed to the discovery of Neurocrine's GnRH antagonist ORILISSA® and Arena's S1P modulator Etrasimod.

Anula Jayasuriya, Co-Founder and Partner, Kidron Capital

Anula Jayasuriya is a private equity executive and venture capitalist. She founded EXXclaim Capital, an early-stage fund advancing innovation and investment in women's health, and co-founded India's first healthcare-focused fund, Evolvence India Life Science Fund. Previously, she was a partner at Skyline Ventures and TVM, and held leadership roles at Genomics Collaborative and Hoffman-La Roche. Anula holds a BA, MD, and PhD from Harvard, an MBA from Harvard Business School, and an M.Phil. in Pharmacology from the University of Cambridge, combining scientific expertise with deep experience in venture investing and global healthcare innovation.

Donna Parr, Managing Partner, Cross-Border Impact Ventures

Donna Parr is Managing Partner at Cross-Border Impact Ventures, with 30+ years in venture and private equity investing and corporate finance. She has managed portfolios across venture and biotech funds and led the private equity and venture group at OMERS. Donna has operational experience as Executive Director of CellAegis Devices and Manager of Business Development in cleantech. She has served on 40 private company boards, and currently sits on Constellation Software, Topicus.com, and other investee companies. Donna holds an MBA from Schulich School of Business and master's degrees in International Relations from the University of Toronto.

Eric Schaefer, Senior Director - Innovation Fund, March of Dimes

Eric Schaefer leads the March of Dimes Innovation Fund, overseeing investments in startups addressing key clinical challenges in maternal and infant health. Previously, he was Vice President of Healthcare Innovation at Coplex, a startup studio developing healthcare ventures with corporate partners, and worked at UnitedHealth Group R&D on innovative investment projects. Eric also brings extensive healthcare provider experience from strategy and corporate development roles at Allina Health and North Memorial Health, combining investment, innovation, and operational expertise to advance transformative solutions in maternal and infant health.

JANUARY 13 - 11AM | AI IN HEALTHCARE

Redefining R&D and Care Delivery with Artificial Intelligence

Artificial intelligence is revolutionizing healthcare by enabling more efficient drug discovery, accelerating clinical trials, and improving patient care. From predictive modeling to molecular design, AI-driven platforms are reshaping how new therapies are developed and delivered.

This panel will bring together investors and thought leaders at the intersection of AI, healthcare, and drug discovery. Panelists will discuss promising use cases, challenges around data quality and regulation, and what differentiates sustainable AI-enabled companies. Hear how AI is transforming both the lab bench and the patient journey.

Miriam Dong, General Partner, ID3 Ventures

Miriam Dong is a General Partner at ID3 Ventures, a Toronto–New York firm backing early-stage deeptech and life sciences across North America. She invests at the intersection of AI and healthcare, focusing on AI-enabled drug discovery, clinical-trial optimization, and tech-enabled care delivery. A former founder and current researcher in venture and AI/ML, she brings an operator–investor lens to data provenance, model validation, regulatory pathways, and biopharma partnerships. Her current interests include scalable platforms and Phase II/III assets in immunology and inflammation. She champions the responsible adoption of AI in biomedicine and collaborates with industry and academia to turn promising science into products.

Sai Jasti, Head of Data Science & Artificial Intelligence, Bayer

Sai Jasti is Head of Data Science and AI at Bayer Pharma R&D, driving digital, data, and analytics initiatives to accelerate drug discovery and embed data-driven decision making across the organization. Previously, he served as Chief Data and Analytics Officer for Global Vaccines at GSK and led global data transformation at AstraZeneca. Sai began his career in strategy and operations at leading consulting firms. He combines scientific, business, technology, and consulting expertise to deliver innovative AI and data solutions, making data science a business-critical capability in pharmaceutical R&D.

Stephanie Oestreich, Managing Director, Myeloma Investment Fund

Stephanie Oestreich is Managing Director of the Myeloma Investment Fund and Chair of the McCloy Alumni Association. She serves on the faculty at MIT and advises SpringBoard Ventures, grIP Venture Studio, Biognosys, Invitris, CelineTx, and OrangeGrove Bio. Previously, she was Chief Business Officer at Galecto, VP at Mnemo Therapeutics, Venture Partner at RA Capital, and Executive VP at Evotec, where she built the North American investment arm and launched an incubator. Stephanie holds a Ph.D. in biochemistry from Harvard Medical School and an MPA from the Harvard Kennedy School, combining scientific and investment expertise.

Venkat Srinivasan, Managing Director, Innospark Ventures

Dr. Venkat Srinivasan is Founder and Managing Director of Innospark, bringing decades of entrepreneurial experience and deep expertise in AI, computational linguistics, and domain knowledge in finance and accounting. He has founded multiple AI-led startups, including eCredit (acquired by ICG) and Rage Frameworks (acquired by Genpact). Venkat holds eight patents, has published over 30 peer-reviewed papers, co-edited two books, and authored The Intelligent Enterprise in the Era of Big Data. He advocates AI transformation grounded in traceability, context recognition, and learning from sparse data through computational abstractions.

Qing Zhang, Partner, LDV Partners

Qing is a seasoned venture investor in Silicon Valley and a thought leader at the intersection of AI, life sciences, and healthcare. She focuses on investments in drug development, precision medicine, and synthetic biology, supporting innovations that translate science into real-world impact. Qing serves on public and private company boards, has held CXO roles as a venture builder, and founded DaVinci Café, a community for deep tech founders and scholars. Previously, she practiced medicine at Singapore General Hospital and conducted research at MIT's Broad Institute. She holds a B.S. and M.D. from Tsinghua University and an MBA from Columbia.

JANUARY 13 - 1PM | ORPHAN & RARE DISEASES

Unlocking Innovation for High-Need, Niche Markets

Orphan and rare diseases affect millions worldwide, yet most conditions lack effective treatments. Increasingly, investors are drawn to this sector because of strong regulatory incentives, faster approval pathways, and the potential for transformative patient impact.

This 50-minute panel convenes investors and strategics focused on rare disease innovation. Panelists will share how they evaluate scientific promise, the role of patient advocacy groups, and the unique challenges of commercializing therapies for small populations. Learn why rare diseases are a growing focus for capital deployment.

Anjan Aralihalli, Founder, Raya Therapeutic

Anjan is Founder of Raya Therapeutics and a Venture Partner at CTI Life Sciences (Canada), with 25+ years of international experience across biotech and pharma, including investor relations, corporate development, venture and angel financing, licensing, sales, marketing, and clinical trial management. He advises multiple biotech companies and serves on the Mid-Atlantic Bio Angels steering committee. Based near Princeton, NJ, Anjan supports ALS and muscular dystrophy research through Wings Over Wall Street, the Robert Packard Center, and the Muscular Dystrophy Association. He holds a BSc from Concordia, an MBA from Queen's University, and an MSc in Biotechnology from Johns Hopkins University.

Jin Lee, Investor, Oxonian Ventures

Dr. Jin Lee is a digital health investor and entrepreneur, passionate about women's health and the autoimmune space. She was formerly the Global Director of Digital Health at Astellas Pharma Inc where she focused on new product development and commercialization globally. Dr. Lee also worked at the innovation centers and venture arms of Humana and Providence St. Joseph Health. Based in Silicon Valley, Dr. Lee is an LP in three angel funds, advises and invests in digital health startups and accelerator programs. She also serves on multiple nonprofit boards, including the American Heart Association and the Healthcare Businesswomen's Association in the past.

Brian Miglionico, Vice President, Business Development, Agios Pharmaceuticals

Brian Miglionico is Vice President, Business Development at Agios Pharmaceuticals, where he leads strategic initiatives to advance corporate growth and portfolio development. He brings broad experience across business development, strategic evaluation, and operational execution in the biopharmaceutical industry. Prior to Agios, Brian held senior leadership roles at Alexion, including Strategy Executive Director and Senior Director, Business Development Operations, contributing to corporate strategy and growth initiatives. Earlier, he served as Associate Director of Corporate and Product Development at Finch Therapeutics Group. Brian began his career at Acceleron Pharma, with roles spanning Regulatory Affairs, Business and Market Development, Quality Control, and Research, and served as Program Lead overseeing clinical, non-clinical, and CMC activities.

Takehiko Sawabe, Director, Beyond Next Ventures

Takehiko Sawabe is a Director on the Biotech Investments Team at Beyond Next Ventures. Prior to Beyond Next Ventures, he was a Managing Director at INCJ, where he was involved with investments in biotech start-ups such as Stella Pharma (IPO on TSE Mothers in 2021), Scohia Pharma etc. He started his career as a medicinal chemist in Meiji Seika in 2000. He was moved to the business development team in 2006, where he achieved some in-license deals with biotechs. Between Meiji Seika and INCJ, he has career experience in Johnson & Johnson and AbbVie. He received a Masters degree from Graduate School of Pharmaceutical Sciences at the University of Tokyo and a MBA from Graduate School of Management, GLOBIS University.

JANUARY 13 - 2PM | CORPORATE VC

Strategic Investment Beyond the Balance Sheet

Corporate venture capital arms provide startups with more than just funding – they bring strategic expertise, industry connections, and potential commercialization pathways. For innovators, corporate VCs can be pivotal partners in navigating complex healthcare markets.

This panel will feature leaders from corporate VC groups sharing what differentiates their approach from traditional venture funds. Panelists will discuss how they balance financial and strategic goals, the types of companies they target, and how they integrate investments into broader corporate priorities.

Tom Gibbs, Investment Director, Debiopharm Innovation Fund

Tom is Senior Investment Director at Debiopharm Innovation Fund, Switzerland where the focus is on investment in digital health companies transforming how drugs are developed and the patient path. Tom is excited to bring his broad experience to the digital health revolution, helping start-ups in Debiopharm's comprehensive portfolio build value, make a medically meaningful impact, and improve drug development. He is currently a Director on the boards of Nucleai, Carevive, BC Platforms, and Immunexpress. Previous board positions include Acteon, Biocartis and GenePOC. He has worked in the commercialization of life science technologies in start-ups and established companies in Europe and the USA (including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm) for longer than he cares to admit. Hands-on experience includes operations, late-stage product development & marketing, business development, and investment.

Jiaping Gu, Partner, Takeda Ventures

Jiaping Gu is a Partner at Takeda Ventures, Inc (TVI). He has more than seven years of experience in public and private life science investments and served on the board of directors at various biotech companies. Prior to joining TVI, Jiaping was Vice President at Hillhouse Capital, where he was a member of the Bioventure team covering private stage biotech investments in the US and Europe. Previously he has more than 10 years of research experience focusing on neurodegeneration as a scientist in the pharmaceutical industry and academic institutions. Jiaping has a Ph.D. in Neuroscience from Rutgers University and B.S. in Biological Sciences from Tsinghua University.

Anthony Vallance-Owen, Senior Investment Manager, We Venture Capital

Anthony is a Senior Investment Manager at We Venture Capital, with 20+ years of experience in business and transactional advice, including M&A, debt, and IPOs. Anthony was with PWC for 15 years, gaining global experience in the UK, North America, and Asia. He qualified as an ACA chartered accountant and completed his MBA at ESADE, Barcelona, Spain. After his MBA Anthony supported Werfen in setting up their Corporate Venture Capital arm, with We Venture Capital being publicly launched in September 2023. In addition, Anthony serves as a director on the board of Zetta and Respiree an observer to the board of OXcan, our portfolio companies.

JANUARY 13 - 3PM | TECHBIO & SYNTHETIC BIOLOGY

Engineering Biology for the Next Wave of Innovation

The convergence of biology and technology is fueling the rise of "techbio" and synthetic biology companies, enabling programmable biology, new materials, and next-generation therapeutics. Investors are increasingly drawn to this interdisciplinary frontier where software meets wet lab.

This panel brings together investors and entrepreneurs pioneering techbio and synthetic biology. Panelists will discuss what excites them in this emerging sector, how they evaluate platforms versus product plays, and where they see the greatest opportunities for long-term value creation.

Chris Yoo, General Partner, Xcellerant Ventures (Moderator)

Dr. Chris Yoo is a serial entrepreneur and visionary in healthcare and life sciences with 25+ years of experience building companies and ecosystems that enable scientific breakthroughs. He co-founded Systems Imagination (AI for drug discovery) and Systems Oncology, and previously founded and exited ventures including MedTrust Online, TransMed Partners, and LabBook. With a PhD in Cell and Molecular Biology, Chris bridges science and entrepreneurship, mentoring startups, investing via angel and venture networks, and teaching at ASU and Grand Canyon University. He serves on multiple boards and leads Yoo & Co Accelerators, driving transformative healthcare innovation and fostering collaborative ecosystems.

Yaron Daniely, General Partner, aMoon Fund

Dr. Yaron Daniely is a General Partner at aMoon Fund, where he co-leads Velocity, aMoon's early-stage investment fund. Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University's Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network. Before leading Yissum, he spent 14 years as a senior executive of private and NASDAQ-traded Biotech companies. Yaron earned his PhD from NYU, served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion.

Cristina Escoda, Co-Founder & Managing Partner, Tachyon Ventures

Cristina Escoda (PhD, MBA) is a venture investor and physicist working at the intersection of biology and technology. She is the founder and Managing Partner of Tachyon Ventures, an early-stage fund focused on techbio and synthetic biology. Her work centers on how programmable biology, AI, and computational tools are reshaping therapies, drug discovery and material innovation. Before founding Tachyon, Cristina built and led companies in payments software and quantum computing hardware. She began her career at D.E. Shaw & Co, the NYC hedge fund. Cristina holds a PhD in Physics from the University of Cambridge and an MBA from NYU Stern, and has spent over fifteen years supporting deep-tech founders through university tech transfer, product strategy, and early venture formation.

Rohit Jain, CIO, HBS Alumni Angels of Northern California

Rohit is CIO for the Harvard Business School Alumni Association NC and serves on its Advisory Board. He is an investor and advisor with Harvard Business School Angels, the Harvard New Venture Contest, and the Innovation Lab at Harvard University, and serves on the Harvard Business Review Advisory Board. Rohit is also VP of Technology, Applications, and Analytics at iRhythm (Nasdaq: IRTC). He previously held leadership roles at IBM, Stanford University, and Upwork (Nasdaq: UPWK), and co-founded Dhobighat.com, a precursor to today's social media companies. He is a Harvard Business School alum.

Nick Naclerio, Founding Partner, Illumina Ventures

Nick is the Founding Partner of Illumina Ventures, where he focuses on building companies at the intersection of technology and human health. Previously, he served as SVP of Corporate & Venture Development at Illumina Inc., leading strategic planning, business development, licensing, investing, and acquisitions. During his six-year tenure, Nick and his team completed ten acquisitions, more than a dozen venture investments, and major transactions including the formation of Helix and GRAIL. He also served as the founding General Manager of Illumina's Enterprise Informatics Business Unit. Before Illumina, Nick co-founded Quanterix and held leadership roles at ParAllele BioScience, True Materials, and Motorola Life Sciences. He holds degrees from Duke, Cambridge, and the University of Maryland.

JANUARY 13 - 4PM | 2026 OUTLOOK: VC PERSPECTIVES

Where Investors See Healthcare Innovation Headed

After several years of volatility, the life sciences investment landscape is beginning to stabilize. Early-stage funding fell sharply from 2021 peaks, but recent quarters show signs of recovery, with total capital invested remaining strong thanks to larger, later-stage rounds. In 2024, U.S. life sciences VC funding climbed 16% year-over-year to reach $30.5 billion, while global investment surged to $48.4 billion – driven by biopharma, AI-enabled drug discovery, and precision medicine.

In this panel, investors will share their perspectives on where the market is heading in 2026. Panelists will discuss which sectors are gaining momentum, how they are navigating selective early-stage funding, and what entrepreneurs should expect when raising capital in the year ahead.

Gary Gershony, Partner, BayMed Venture Partners (Modertaor)

Dr. Gershony is Director of Cardiovascular Research, Education, and Technology at John Muir Cardiovascular Institute and a leading interventional cardiologist with 20+ years of practice. Trained at the University of Toronto and Emory University under Dr. Andreas Grüntzig, he previously led UC Davis's Cardiac Catheterization Labs. He co-founded Vascular Solutions, Inc. and AngioScore, Inc., holding multiple patents and guiding successful IPOs and acquisitions. A principal investigator in numerous trials, Dr. Gershony is board certified, a Fellow of multiple cardiology societies, adjunct faculty at Stanford Biodesign, and an active investor and mentor in early-stage MedTech companies.

David Berry, Managing Partner, Averin Capital

David is a career innovator, entrepreneur, and investor, and co-founder of Averin, aiming to transform healthcare through technology for faster, more affordable patient outcomes. He has co-founded 30+ companies across life sciences and sustainability, including seven valued over $1B, and was previously a General Partner at Flagship Pioneering. Recognized as a World Economic Forum Young Global Leader and MIT Technology Review Innovator of the Year, David holds 200+ patents. He earned a B.S. in Brain and Cognitive Sciences from MIT, a Ph.D. in Biological Engineering from MIT, and an M.D. from Harvard Medical School.

Gautam Kainth, Partner, TCP Health Ventures

Gautam joined TCP Health Ventures in 2017, leading early-stage investments in healthcare and technology. He serves on the boards of Tioga Cardiovascular, Adona Medical, Akura Medical, Plexaa, and as a board observer for Mindset Technologies. With 20+ years of investment experience and $1B+ deployed capital, he previously worked at Religare Global Asset Management, Evolvence India Fund, and JP Morgan. Gautam holds an MBA from the University of Delhi and completed the Health Innovation Management program at Imperial College London. He was named among "40 Under 40 Alternative Investment Professionals" in 2019.

Bibi Sattar Marques, Partner, Buenavista Equity Partners

Bibi is Partner and Board Member at Buenavista Equity Partners Portugal, leading the development of the firm's Venture Capital arm and strengthening its Iberian leadership. With 18+ years in the financial sector, she gained expertise at PwC and ANACOM in auditing, corporate finance, and regulation, including work with the Regulatory Accounting Group of European electronic communications regulators. Since 2017, she has launched nine venture capital funds with €100M+ under management. Bibi also serves on the GRACE Advisory Board, combining financial acumen and venture expertise to drive innovation and investment in the region.

Chensu Wang, Investment Manager, Yonjin Venture

Chensu is an Investment Manager at Yonjin Venture, specializing in innovative therapies and medical devices. Previously, she was a Consultant at Boston Consulting Group (BCG), advising global biopharma and medtech firms. Before joining BCG, she served as a Senior Scientist at Pfizer, focusing on immuno-oncology drug discovery. Chensu holds a PhD in Biomedical Engineering from UT Southwestern Medical Center, with postdoctoral training in immuno-oncology at Massachusetts Institute of Technology, and a BS in Biomedical Engineering from Southeast University, China.

JANUARY 12 | 9AM-5PM

INNOVATOR'S PITCH CHALLENGE TRACK 1

Location: Golden Gate C2

	Pitch Company			
9:00 - 9:50 AM **SESSION #1** **THERAPEUTICS** *Regenerative Medicine & Healthy Aging*	Immorta Bio	Immunis	JangoBio	Sunac Tx
10:00 - 10:50 AM **SESSION #2** **THERAPEUTICS** *Next-Generation Oncology Therapeutics*	AlphaOnco	BCN Biosciences	PlusVitech	Sebastian Biopharma
11:00 - 11:50 AM **SESSION #3** **THERAPEUTICS** *Chronic Disease and Inflammation*	BioSuperior Technology	InStatin	Pure Green Pharmaceuticals	TesoRx Pharma
1:00 - 1:50 PM **SESSION #4** **THERAPEUTICS** *Neurology & CNS*	Delphian Therapeutics	Galibra Neuroscience	NeuroHope Therapeutics	ReEngage Therapeutics
2:00 - 2:50 PM **SESSION #6** **MEDICAL DEVICES** *Surgical & Procedural Innovations*	Bayou Surgical	GI Bionics	NousQ	Opportunity Health
3:00 - 3:50 PM **SESSION #8** **THERAPEUTICS** *Advanced Cell & Gene Therapies*	Celaid Therapeutics	Inomagen Therapeutics	Tidewave Biotech	VerImmune
4:00 - 4:50 PM **SESSION #10** **THERAPEUTICS** *Therapies for Chronic & Specialized Conditions*	Alphyn Biologics	Arkayli Biopharma	ilerabio	VitalTE Life Sciences

JANUARY 12 - 9 AM | SESSION 1 - THERAPEUTICS

Regenerative Medicine & Healthy Aging

This session features therapeutics that target the biological drivers of aging, regeneration, and tissue restoration. Companies are pioneering approaches that modulate stem cell activity, rejuvenate endocrine and immune pathways, and restore systemic function. These innovations aim to extend healthspan and address age-related decline at its root.

IMMORTA BIO
A Scientific Longevity Company

Immorta Bio is a longevity biotechnology company developing the first dual-mechanism platform to reverse the biological drivers of aging and the diseases that arise from them, including cancer. Our approach both eliminates harmful senescent cells with first-in-class senolytic immunotherapy (SenoVax™) and restores youthful regenerative capacity using patient-derived iPSC-based rejuvenation (StemCellRevivify™). In validated aging models, combining both platforms produced dramatic rejuvenation effects, including more than doubling lifespan and strong improvements in tissue recovery. In liver-failure models and other organ-damage settings, the dual-platform approach generated significant regenerative outcomes. In tumor models, SenoVax™ showed robust regression signals in breast, lung, pancreatic, and glioma cancers. Supported by 26 patents and leading scientific collaborators, Immorta Bio plans to begin Phase 1 and Phase 1/2a trials in the first half of 2026.

Immunis

Immunis is a clinical-stage biotech at the intersection of regenerative and longevity medicine, pioneering health-focused therapeutics targeting age and immune-mediated muscle and metabolic diseases. Immunis developed IMM01-STEM, a novel stem cell-derived secretome product. IMM01-STEM is a complex biologic containing bioactive factors known to modulate immune signals and to regulate muscle regeneration. IMM01-STEM stimulates multiple cellular pathways, and we believe that its multi-factorial mechanism of action may prevent or reverse the underlying age-related biological deficits that impair muscle regeneration. Therefore, IMM01-STEM has the potential to improve physical function, enhance metabolism, and promote a higher quality of life into old age.

JangoBio®
Living healthier lives, longer

JangoBio's therapeutic strategies are designed to restore tissue function back to youthful levels using the regenerative power of stem cells. To this end the company has developed a hormone-producing organoid bioengineered to produce sex hormones. This therapy restores hormone balance back to youthful levels and extends healthy longevity by as much as 32% (in a rodent castration model). Aside from this life extension advantage that is equivalent to 17 human years, this transformational therapy has multiple additional applications in mitigating diseases of aging. A second product, JangoRenew, has been bioengineered to regenerate articular joints for the treatment of osteoarthritis. Pilot studies in pet owner dogs demonstrate dramatic improvements in pain and mobility that pave the way for human clinical trials. Commercialization of JangoRenew in the human and companion animal markets would provide physicians/veterinarian access to a first in class, off-the-shelf therapy, for the treatment of osteoarthritis.

SUNAC
THERAPEUTICS

Sunac is a biotech pioneering regenerative gene therapy for osteoarthritis and degenerative disc disease. Our mission is to reverse the cellular drivers of joint degeneration, delivering a durable, single-dose treatment that restores long-term function. With a $10B+ immediate addressable market and a broader $160B economic burden, Sunac's therapy addresses one of the largest unmet needs in spine degeneration.

- Mechanism: Restores expression of a key gene to epigenetically remodel chromatin in senescent cells.
- Outcome: Senescent cells revert to healthy, functional states—resuming extracellular matrix production, halting inflammatory cytokine release, and regaining proliferative capacity.
- Administration: A one-time, intra-articular injection performed in the physician's office.
- Demonstrated efficacy in human tissue and animal models.
- Preclinical studies show therapeutic benefit in >80% of patient samples.
- Designed to address disease progression, not just symptoms.
- Funding supports completion of a Phase 1/2b clinical study within 36 months.

JANUARY 12 - 10 AM | SESSION 2 - THERAPEUTICS

Next-Generation Oncology Therapeutics

This session presents novel therapeutic strategies designed to overcome cancer resistance mechanisms, enhance anti-tumor precision, and improve treatment durability. Companies leverage engineered biologics, immune-stimulatory mechanisms, and targeted molecular modulation to address high-unmet-need cancers.

AlphaOnco

A Natural Nanomedicine For Cancer Treatment

AlphaOnco is pioneering a novel, non-invasive prostate cancer therapy using magnetosomes—naturally derived magnetic nanoparticles—combined with focused low-intensity ultrasound. This unique approach enables localized tumor destruction at moderate temperatures (43–45°C) without the need for general anesthesia, surgical procedures, or radiotherapy. The treatment is designed for outpatient use, significantly reducing cost, patient risk, and recovery time. With 14 global patent families, validated efficacy in multiple tumor models, and preclinical evidence showing full tumor disappearance with no regrowth, AlphaOnco is positioned to transform focal therapy in prostate cancer. The company is raising €5M to advance to clinical trials by 2026.

BCN Biosciences is a pre-clinical therapeutics company which has developed first-in-class inhibitors of the protein SSB2, targeting epithelial cancers caused by mutations of MAP Kinase pathway. Activation of SSB2 induces mitotic catastrophe and kills mutant cancer cells that have lost their ability to control cell-cycle arrest. These include all RAS and RAF mutations as well as EGFR driven cancers. BCN therapies are effective in metastatic colorectal, pancreatic, lung and triple-negative breast cancers among others. Importantly, these drugs can be effective in tumors, resistant to KRAS inhibitors such as Sotorasib(Amgen) BRAF inhibitors such as Encorafenib(Pfizer). BCN Bio is advancing BCN077 as the lead candidate that targets bRAF V600 mutant metastatic colorectal cancer as the first indication in human. BCN077 is ready for IND-enablement studies. BCN has developed a class of small molecules that include optimized candidates to target KRAS mutant Colorectal or Triple Negative Breast Cancer as the next indications.

Plus Vitech

PlusVitech is a clinical-stage biotech developing PVT-1: the first oral, non-toxic, home-administered complete treatment for advanced non-small cell lung cancer. By repurposing the FDA/EMA-approved drug aprepitant as an NK1R antagonist and enhancing it 10× with proprietary CESS® nanotechnology, PVT-1 induces tumor-selective apoptosis. Guided by real-time liquid-biopsy companion diagnostics and AI-powered Decision Support Software, it has achieved complete remissions in terminal patients. With Phase I/II ongoing, €2.5M EIC grant secured, near 8m€ raised (between private and public funding), and big-pharma licensing discussions active.

SBP Sebastian BioPharma

Sebastian BioPharma is a preclinical oncology company developing first-in-class antibody–oligonucleotide conjugates (AOCs) designed to overcome the complex biological mechanisms that drive resistance to immunotherapy in solid tumors. Our proprietary OligoBridgeX platform enables precise 1:1 ligand-to-oligonucleotide scaffold assembly, preserving antibody function while allowing coordinated modulation of multiple intracellular pathways with dual-siRNA payloads. Our lead program, SBP-001, applies this architecture to reprogram immune-resistant colorectal and esophageal tumors and is advancing into in vivo validation. The company's foundational science originated in Dr. Eli Gilboa's laboratory at the University of Miami and is supported by more than ten peer-reviewed publications. Sebastian BioPharma holds an exclusive UM intellectual property license and is prosecuting additional patents as a sole entity to strengthen its IP position around dual-AOC therapeutics. Backed by a seasoned scientific founding team and early accelerator traction, Sebastian BioPharma is building a pipeline of modular AOC therapeutics to address high-unmet-need, immunotherapy-resistant cancers.

JANUARY 12 - 11 AM | SESSION 3 - THERAPEUTICS

Chronic Disease & Inflammation

This session highlights therapeutics addressing chronic inflammatory, respiratory, metabolic, and pain-related conditions. These companies develop multi-pathway mechanisms, improved formulation strategies, and targeted delivery systems aimed at mitigating disease progression and improving long-term patient outcomes.

BioSuperior Technology is advancing BioSurf™, a next-generation synthetic lung surfactant engineered to restore lung function and deliver therapeutics directly to the deep lung. The company's lead indication—Acute Respiratory Distress Syndrome (ARDS)—is a life-threatening condition with 40% mortality and more than $27 billion in annual U.S. healthcare costs. Unlike prior surfactant products, BioSurf™ contains a full-length, fully active surfactant protein analog that provides superior biophysical stability, scalability, and safety. In animal models of ARDS, BioSurf™ has demonstrated the ability to restore oxygen exchange and improve lung mechanics. Supported by strong IP and non-dilutive NIH and NSF funding, BioSuperior is advancing toward IND-enabling studies and a Phase Ib/IIa clinical trial to deliver the first pharmacologic therapy for ARDS.

InStatin is pioneering inhaled statins as groundbreaking alternatives to current asthma/COPD treatments including injected biologics, inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA). While ICS use can lead to severe side effects (i.e., pneumonia, adrenal insufficiency, cardiovascular events), oral statins have shown potential in asthma/COPD but suffer from poor airway penetration following oral delivery (are undetectable in human airway brush biopsies). Inhaled statins offer optimal lung concentrations with minimal systemic exposure. Statins, considered "everything drugs" along with the GLP1s, are known for their success in reducing heart attacks and strokes, also show promising potential in asthma/COPD in reducing inflammation and lung tissue decline. InStatin's team is world renowned in respiratory medicine and inhalation drug delivery. Series A Funding is sought for 2 side by side human Proof-of-Concept studies in both asthma and COPD (with same product). This novel approach is a paradigm shifting, safe, and potentially more effective asthma/COPD therapy.

Pure Green Pharmaceuticals is at clinical phase II with excellent efficacy and safety data from 2 published clinical trials using our patented sublingual CBD tablet to relieve diabetic neuropathy pain. $6M+ already raised with $2M+ NIH funds ready to deploy for the next clinical trials to complete clinical phase II and then M&A company to major pharmaceutical to complete clinical Phase III and launch. More information to follow.

TesoRx Pharma and its subsidiary, Lipac Oncology, are clinical-stage companies utilizing a novel Neoliposomal™ delivery system. This delivery system addresses significant challenges like poor solubility, low permeability, and systemic toxicity, creating breakthrough therapies. Their primary clinical candidates are for intracavitary carcinomas (Lipac) and oral Testosterone Replacement Therapy (TRT) (TesoRx). LiPaxTM, our intracavitary paclitaxel formulation has demonstrated a 63% CR and 83% disease free survival (DFS) in Low and Intermediate NMIBC. Additional treatments such as Malignant Pleural Effusion (MPE) are also being pursued. TesoRx's TRT bypasses the liver via lymphatic absorption, demonstrating clinically enhanced bioavailability with greater than 30% compared to approved oral formulations, with fewer side effects and potentially once a day dosing.

JANUARY 12 - 1 PM | SESSION 4 - THERAPEUTICS

Neurology & CNS

This session features innovative therapeutic approaches for neurological and CNS diseases. Companies present differentiated strategies including neuroprotective pathways, gene-related modulation, and multi-target central mechanisms engineered to address migraine, neurodegeneration, and CNS injury.

Delphian Therapeutics

Migraine affects 1.2B people and represents a $31 billion U.S. TAM, yet current therapies fail 80% of patients. Delphian Therapeutics is optimizing multi-modal endocannabinoid system (ECS) modulation to treat migraine, a disease with complex pathophysiology for which single-target approaches are limiting. Our issued U.S. patents are based on rigorous, peer-reviewed preclinical evidence, and protect the only optimized formulation of cannabidiol and Δ9-THC, providing a defensible, proprietary, best-in-class formulation. Phase 1 is well underway advancing not only S1-221 for migraine but a platform with potential across headache, pain, and CNS disorders. A gold-standard 2023 human trial at UCSD demonstrated safety & efficacy to the FDA endpoints for migraine, suggesting greater efficacy than CGRP with no major AEs. Big Pharma has validated the class, led by Jazz $7.2B acquisition of GW Pharma in 2021. AbbVie, Novartis, Otsuka, and Teva are also participants in the category. Delphian is well-positioned in this rapidly emerging market.

GALiBRA NEUROSCIENCE

Galibra Neuroscience is a preclinical-stage company developing gene therapies for GABA-related neurological disorders. At Galibra Neuroscience, our mission is to lead innovation in gene therapy for GABA disorders. We are committed to the translation of cutting-edge science to meet urgent patient needs. We aim to empower lives and set new standards for excellence in personalized healthcare. We leverage strong partnerships with leading academic institutes and patient advocacy groups to streamline bench to bedside translation of novel disease-modifying therapies.

NeuroHope Therapeutics, Inc.

NeuroHope Therapeutics, is seeking to develop and commercialize nanotherapeutics that can mitigate destructive neuroinflammatory responses resulting from central nervous system trauma and improve functional recovery and quality of life for patients experiencing spinal cord and brain injury. Our core technology consists of an amphiphilic cationic graft copolymer (PgP) invented by co-Founder Dr. Jeoung Soo Lee and covered by US patent #10, 232, 050 B1. PgP spontaneously self-assembles into polymeric micellar nanoparticles, providing a core in which hydrophobic drugs can be encapsulated and positively-charged outer shell that has high binding for negatively-charged cell membranes, enabling prolonged residence time and local drug delivery at the site of injury. Our lead asset is rolipram-loaded PgP (Rm-PgP) for the treatment of acute spinal cord injury (SCI). In rodent preclinical models, a single intrathecal injection of Rm-PgP maintains rolipram in the cerebrospinal fluid for over 7 days, mitigates neuroinflammation, and improves motor functional recovery.

ReEngage Therapeutics

ReEngage is focused on developing therapeutics that modify epigenetic targets implicated in aging-related disorders, including neurodegeneration and cancer. We have developed novel small molecule inhibitors to a metabolic target, acetyl co-A synthetase (ACSS2), which is known to fuel epigenetic gene regulation. We have shown that our molecule MTB-9655 is safe and tolerable in humans, and now have elucidated its mechanism of action - downregulating expression of DNA damage repair genes, which contribute to chemo resistance. Further, MTB-9655 plus chemo in colorectal cancer (CRC) patient-derived xenograft models was shown to extend median survival by 50% over chemo-alone. We plan to initiate a phase 1b/2a study for third line metastatic colorectal cancer in 2026, led by PI Dr. Scott Kopetz of MD Anderson.

JANUARY 12 - 2 PM | SESSION 6 - MEDICAL DEVICES

Surgical & Procedural Innovations

Focusing on new technologies that improve the safety, efficiency, and precision of surgical and procedural care, this session highlights companies advancing visualization tools, minimally invasive interventions, and workflow-enhancing platforms that reduce complications and improve outcomes.

Bayou Surgical was founded in 2016 by surgeons in the Texas Medical Center to address one of the greatest unmet needs in minimally invasive surgery - to restore vision from the soiled surgical camera without disrupting the surgical procedure. During laparoscopic and robotic surgery, the lens of the surgical endoscope was commonly soiled from blood, tissue, and energy device debris. Restoring visualization through the soiled camera required the surgeon to stop operating, remove the endoscope from the patient's body, clean it manually, commonly apply a defogging solution, reinsert the camera in the patient's body, and then resume the procedure.

GI Bionics has developed fecoBionics, a breakthrough technology platform for diagnosing and treating defecation disorders, including fecal incontinence and constipation - conditions poorly addressed by current solutions. fecoBionics integrates three diagnostic procedures into one device, enabling accurate assessment to move from specialty centers into GI and OBGYN clinics. The platform is FDA 510(k) cleared, supported by a strong IP portfolio, and designed to fit seamlessly into existing reimbursement frameworks without requiring capital investment from clinics. To date, more than $15 million has been spent on development, validation, and clinical trials. The market for defecation disorders remains significantly underserved, with high demand for effective innovation. GI Bionics' founding team brings a proven track record of successfully developing and exiting medical device companies, positioning the company to transform care and capture a substantial market opportunity.

NousQ is the inventor of CLiKX, the world's first handheld robotic device with sensors to treat glue ears. Otitis Media with Effusion (or "glue ears") is the foremost reason why children visit a doctor. It affects the hearing of millions of children worldwide annually. When conservative treatments do not work, surgery is required to place a tiny ventilation tube to drain the fluid from the middle ear. Given the invasive nature of the current surgery, an operating theatre, general anaesthesia and a large non-portable surgical microscope is needed. With CLiKX, we are able to move the surgery out of the operating theatre into the clinic using local anaesthesia and without the large surgical microscope. This drastically reduces treatment time, procedure costs and the long waiting time for surgery. The total addressable market for such a surgery is estimated to be about 120 million per annum globally.

Opportunity Health is building Yarnasa, an automatic, self-applicable medical device that removes airway obstructions using CO₂-powered, multi-stage Venturi pulses—consistent suction at the push of a trigger, reducing user dependence in stressful events. Target settings: elderly care homes, ambulances/EMS, restaurants and public transport. EU MDR Class IIa pathway is underway with pre-clinical validations in collaboration with the University of Navarra (LABIM) and IDIS. IP protected via a European patent filing (2025). Business model combines device sales with recurring revenues from single-use consumables and an annual maintenance/certification program (AED-style). We are raising €2.5M seed to complete MDR activities, industrialization and pilots, and to prepare the US route.

JANUARY 12 - 3 PM | SESSION 8 - THERAPEUTICS

Advanced Cell & Gene Therapies

Presenting next-generation cell and gene therapies with curative potential, this session includes platforms enabling targeted immune activation, engineered hematopoietic stem cell expansion, tumor-targeting viral structures, and antigen-presenting technologies that broaden accessibility and durability of advanced biological treatments.

Inomagen Therapeutics, is a private, preclinical stage biotechnology company pioneering a gene therapy to improve the treatment of atrial brillation. Inomagen has intellectual property and proof of concept data for both the gene and the gene delivery system. Inomagen has a strong and experienced team of industry veterans and key opinion leading cardiovascular physicians to engage in management and advisory roles, including those with extensive domain experience in gene therapy, cardiology, AF therapeutics, medical device, clinical studies, and venture capital. The market size for Inomagen's gene therapy products is $10.2B.

Celaid Therapeutics, a University of Tokyo and University of Tsukuba spinout, develops next-generation cell and gene therapies based on its proprietary selective ex vivo hematopoietic stem cell (HSC) expansion technology. By safely and efficiently expanding human HSCs, Celaid aims to transform treatments for hematologic, genetic, and ischemic diseases. Its lead program, CLD-001, targets severe pediatric non-malignant disorders such as aplastic anemia, primary immunodeficiency, inherited metabolic disorders, and sickle cell disease—conditions with limited curative options beyond allogeneic HSC transplantation (HSCT). Current HSCT faces major challenges including donor shortages, HLA mismatches, and transplant-related complications like GvHD. CLD-001 addresses these issues by using frozen cord blood from banks as the cell source and overcoming low HSC counts through Celaid's expansion platform. By providing HLA-optimized, bone marrow–engrafting HSCs, CLD-001 is expected to improve patient outcomes and significantly increase overall survival following transplantation.

Tidewave Bio is a biotechnology company pioneering a universal, off-the-shelf antigen-presenting cell (APC) therapy platform designed to transform the treatment of solid tumors. Current cell and gene therapies are limited by patient-specific manufacturing, narrow antigen targeting, and high costs that restrict access. Tidewave's platform overcomes these barriers by delivering a broad repertoire of tumor antigens in a single, scalable product that is tumor type–agnostic, rapidly available, and cost-efficient. Converted into a patient-specific precision medicine in real time using tumor biopsy material, the therapy is designed to activate durable and potent immune responses against the full complexity of solid tumors while avoiding the logistical and financial burdens of autologous approaches. Headquartered in Los Angeles, Tidewave Bio is advancing its lead program toward clinical development, with a mission to expand access to next-generation cancer immunotherapies for all patients, regardless of tumor type, setting, or resource availability.

VerImmune is a U.S. and Singapore co-headquartered biotech company pioneering Virus-inspired Particles (ViPs): self-assembling protein nanocarriers that mimic viral structural geometry to precisely deliver medicines to targeted tissues. This breakthrough delivery platform enables highly efficient treatments for cancer and autoimmune diseases. Our first-generation ViPs, inspired by papillomavirus capsids, naturally bind to epithelial tumors and form the foundation of our lead oncology program, VERI-101, with first-in-human trials expected in 2026. To date, VerImmune has raised US $16 million in total which includes revenue from partnerships and collaborations with major pharmaceutical companies ($4.5M revenue since 2022). We are now raising ~US $10 million Series A to achieve first-in-human proof of concept and expand our therapeutic pipeline. The round is projected to deliver 3–5× value growth within 24–36 months, unlocking multiple pharma partnership, licensing, and exit opportunities across oncology and immune-related indications.

JANUARY 12 - 4 PM | SESSION 10 - THERAPEUTICS

Therapies for Chronic & Specialized Conditions

Therapeutics in this session address dermatologic disease, hormonal imbalances, women's health conditions, and pediatric vascular anomalies. Companies present precision formulations and multi-target mechanisms designed to improve safety, convenience, and quality of life for chronic and underserved patient populations.

Alphyn is developing a pipeline of unique multi-target topical therapeutics for dermatology. Our Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action, to treat individual diseases in multiple ways. Highly important, drugs from our platform have strong safety, side effect, patient tolerability profiles. Alphyn's first drug, ZH, completed Phase 2a clinical trials in atopic dermatitis (AD) known as eczema ($41B market). Results demonstrated superiority to competitive drugs, indicating ZH potential as "drug of choice". Phase 2b clinical trial underway with blinded results better than Phase 2a. ZH directly treats AD's four interconnected problems: inflammation, bacteria, itch, and dry skin. To be effective, an AD drug must directly treat all. Competitive AD drugs primarily direct-target only inflammation forcing the body to eventually tackle the others. Alphyn's second drug (molluscum) completed proof-of-concept human trials; results superior to current therapies paving the way to breakthrough treatment.

Arkayli Biopharma's mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our lead product candidate, ARK001, has the potential to be the first FDA-approved non-systemic topical (applied to the skin) treatment for infantile hemangioma (IH).

Ilerabio is a clinical stage biotech company innovating at the intersection of pharmaceuticals and natural compounds to create and patent effective, affordable therapies starting with a novel prescription therapy for Polycystic Ovary Syndrome, a chronic condition and the leading cause of female infertility affecting over 40 million women globally for which there are no FDA approved therapies.

We're reducing complexity in hormone therapy with long acting hydrogel microsphere injections—a platform designed to deliver steadier hormones with far greater convenience. Today, we're raising $3.8M to finish key pre IND steps for our lead asset VIT 200, which is bioidentical testosterone. . The goal is steady, therapeutic levels with a simple, subcutaneous injection enabling 1 month treatment intervals.

JANUARY 12 | 1PM-5PM

INNOVATOR'S PITCH CHALLENGE TRACK 2

Location: Golden Gate C3

	Pitch Company			
1:00 - 1:50 PM **SESSION #5** **MEDICAL DEVICES** *Therapeutic & Rehabilitation Devices*	Aevice Health	ATDev	brain4care	ROCESO TECHNOLOGIES
2:00 - 2:50 PM **SESSION #7** **DIAGNOSTICS** *Rapid Point-of-Care Diagnostics*	Ad Astra Diagnostics	PranaQ	Rapid Infection Diagnostics	Transformative Biotech
3:00 - 3:50 PM **SESSION #9** **MEDICAL DEVICES** *Cardiovascular Support & Monitoring Devices*	BMI OrganBank	CoraVie Medical	Frontier Bio	Venstra Medical
4:00 - 4:50 PM **SESSION #11** **ENABLING TECHNOLOGIES** *Innovations in Imaging, Biosensing & Molecular Platforms*	eSensorem	Fischer Imaging	Imaginostics	Monod Bio

JANUARY 12 - 1 PM | SESSION 5 - MEDICAL DEVICES

Therapeutic & Rehabilitation Devices

This session showcases medical devices that enhance rehabilitation, restore functional mobility, and support neurological and respiratory recovery. Solutions include robotic rehabilitation, neuromodulation for developmental disorders, and intelligent wearable monitoring for chronic respiratory disease.

Aevice Health is a Series A MedTech company that developed the world's smallest smart wearable stethoscope to help patients manage chronic and acute respiratory diseases. With over 300 million people worldwide affected by asthma, children are particularly vulnerable as they often cannot express early symptoms, leading to silent deterioration and preventable hospitalizations. To address this, we created AeviceMD, the world's smallest FDA-cleared wearable stethoscope for continuous remote respiratory monitoring. AeviceMD streams objective lung sound data to clinicians, enabling earlier intervention, fewer readmissions, and better long-term disease control, while giving families peace of mind. Backed by leading investors across the US, Japan, and Singapore, including Cedars-Sinai Medical Center, Denka, A&D Company, East Ventures, and the Singapore Government, Aevice Health has raised over US$10M. AeviceMD is cleared in the US and Singapore, with TGA and PMDA approvals underway, and is currently deployed in hospitals in Singapore and the US.

Assistive Technology Development, (ATDev) was founded with a clear mission: mobility for all. Our flagship product, Reflex, is a telehealth-enabled robotic knee rehabilitation device that brings physical therapy into the home. Each year, more than 1 million people undergo total knee replacement surgery in the U.S., yet access to high-quality rehabilitation is limited by distance, cost, and provider shortages. Reflex is FDA-registered and uniquely delivers both passive range of motion and active resistance training in a lightweight, easy-to-use device. It integrates real-time data sharing, daily strength measurement, and proprietary alignment safeguards, enabling patients to recover safely without constant supervision. Reflex is already in limited market release through distribution partners and clinical pilots, demonstrating strong patient and provider interest. ATDev is building an ecosystem of affordable robotic mobility solutions that restore independence, reduce healthcare costs, and redefine recovery.

brain4Care is a pioneer in medical device innovation, introducing an FDA-cleared, non-invasive Intracranial Pressure (ICP) Dynamics monitoring technology. Traditional ICP monitoring has been limited to addressing crises like ICP Hypertension, leaving a significant data gap in the continuous monitoring and early warning signal of patients with brain disorders. Our groundbreaking technology eliminates the need for invasive procedures and leverages AI to generate new neurological markers. Currently, only 220,000 patients globally benefit from ICP monitoring, primarily in severe cases such as Traumatic Brain Injury (TBI), Stroke, and Hydrocephalus. However, brain4Care's technology extends its reach to millions of patients. With a presence in 75 hospitals and clinics, backed by 83 publications and 12 patents, brain4Care boasts robust intellectual property protection covering over 85% of the global market. We're targeting an $8 billion global market opportunity with our technology aiming to enhance patient care outcomes while reducing healthcare costs.

Roceso Technologies is a world leading neurorehabilitation technology company based in Singapore. Its soft robotic and software solutions provide functional assistance and interactive gamifications to patients with limb motor function impairments during rehabilitation and daily living. The company's flagship product, the EsoGLOVETM, is one of the world lightest hand rehabilitation and exoskeleton devices offering top functionality and comfort. Founded in 2016, Roceso Technologies is ISO13485:2016 certified and EsoGLOVETM Hand Rehabilitation System has been registered with FDA, approved by EU CE, Singapore HSA, Japan FDA, Korea FDA, Malaysia MDA and Australia TGA. On top of EsoGLOVETM system, Roceso Technologies is also offering rehabilitation assessment, gamification and platform technologies. The company has clinical partners around the globe and distribution network in more than 20 countries."

JANUARY 12 - 2 PM | SESSION 7 - DIAGNOSTICS

Rapid Point-of-Care Diagnostics

This session features diagnostic platforms capable of delivering rapid, actionable results at or near the point of care. Technologies include mass-spec-based assays, fingertip diagnostics, mobile testing platforms, and direct-to-PCR systems designed to bypass conventional laboratory bottlenecks.

Ad Astra Diagnostics is investor-ready and uniquely de-risked, offering significant venture-style returns in the near term. The company is set to transform healthcare by moving testing from central labs to where patients and providers are to enable fast health decisions that save time, money and lives. Its QScout AI-driven mobile diagnostics platform gives results patient-side including a 2-minute complete blood count in QScout CBC, the fastest need-to-result complete blood count (the most ordered test and first line of triage). Backed by a $12+M BARDA government contract, QScout also reports an early marker for infection including sepsis. Its high-margin, recurring revenue business model is designed to provide central lab quality results at a low cost.

PranaQ is transforming sleep diagnostics and care monitoring. We are addressing the massive, underserved market of over 1 billion people worldwide affected by sleep apnea, millions of whom remain undiagnosed due to limited access to testing. At the same time, we enable more effective value-based care amid the rise of multi-modal sleep apnea treatment solutions Our flagship product, TipTraQ, is an FDA 510(k)-cleared, AI-powered wearable solution that delivers clinical-grade sleep apnea diagnosis and monitoring from a single fingertip sensor—simplifying testing and eliminating the complexity of traditional sleep studies. Backed by leading venture and strategic investors and validated through clinical trials at top hospitals, we are now expanding nationwide through sleep clinics, hospitals, and telehealth partners. We are raising capital to scale sales and marketing and solidify our position as the leader in simple, accurate, and accessible home sleep testing.

Rapid Infection Diagnostics leverages advanced mass spectrometry to enable a suite of rapid diagnostic tests that reduce microbiology testing times from days to hours. RID's mission is to save lives through RAPID microbial analysis. RID technology enables the fastest and most comprehensive microbiology testing workflow for large microbiology laboratories."

Transformative Biotech is advancing our patented direct-to-PCR technologies that eliminate the complex extraction step, making gold-standard molecular testing accessible anywhere. Forged during the pandemic, our platform was validated on more than 590,000 clinical samples at Summit Biolabs, a former CLIA-certified laboratory in Colorado, and is protected by U.S. Patent #12,344,889, with five additional patents pending. The technology supports both swab and saliva samples for viruses and bacteria, delivering results up to 7× faster and at 7× lower cost than conventional PCR. Future applications aim to enable instrument-free handheld PCR devices connected to digital interfaces for point-of-care and at-home use through internal development and partner integration. Our impact: enabling access to affordable, accurate and rapid PCR testing for infectious diseases @ ANYWHERE™, improving diagnosis and treatment to help save millions of lives each year.

JANUARY 12 - 3 PM | SESSION 9 - MEDICAL DEVICES

Cardiovascular Support & Monitoring Devices

This session highlights breakthrough cardiovascular technologies including implantable pressure monitors, organ preservation systems, living vascular grafts, and next-generation percutaneous ventricular assist devices. Each solution seeks to improve survival, reduce complications, and advance cardiac and transplant care.

BMI OrganBank has received an FDA Breakthrough Device Designation for its flagship technology, designed to enhance kidney transplant outcomes with improved organ assessment and preservation methods. Developed in collaboration with transplant surgeons at Duke University, preclinical data supports the potential for profound improvements over the current standard of care. BMI plans to submit an Investigational Device Exemption (IDE) early next year to initiate its clinical study. BMI OrganBank has completed due diligence and secured a strategic investment from the National Kidney Foundation as well as funding from several prominent angel funds (Band of Angels, Golden Seeds) with deep expertise in medical devices. A deal memo is available to select investors.

CoraVie Medical is revolutionizing hypertension management with an implantable, ultrasound-based blood pressure monitor that automatically monitors day and night to capture dangerous blood pressure patterns missed by intermittent and short-term approaches. Paired with a connected data and analytics platform, CoraVie seamlessly integrates its insights into clinical workflows and engages patients through personalized feedback and co-interventions to shorten the time to optimal blood pressure control and reduce the risk of a devastating stroke.

Frontier Bio is a regenerative medicine company developing a tissue-engineered vascular graft (TEVG) designed for cardiovascular and dialysis patients. This living graft aims to integrate with the patient's body, offering a durable, biological alternative to synthetic grafts. Our tissue engineering expertise also enables us to create sophisticated human tissue models, such as a blood-brain barrier on-a-chip. These models help accelerate the development of therapeutics by being a faster and better animal alternative. We've generated $5.5M in sales so far and were profitable in 2024.

VenstraMedical is developing an advanced catheter-based percutaneous ventricular assist device (pVAD) designed to address the rapidly growing $2B market for temporary mechanical circulatory support. Our low-profile pump collapses into a 9F catheter for minimally invasive delivery and expands in the heart to deliver over 7L/min of flow—providing full cardiac unloading for patients in cardiogenic shock and other indications. This combination of ultra-small access size and high flow is unique among current pVAD technologies and is engineered to reduce vascular complications while enabling broader clinical use. VenstraMedical's platform is protected by eight issued patents and has been recognized in Forbes for its innovative approach to cardiovascular support.

JANUARY 12 - 4 PM | SESSION 11 - ENABLING TECHNOLOGIES

Innovations in Imaging, Biosensing & Molecular Platforms

This session brings together platforms redefining how clinicians visualize, measure, and interpret human biology. Innovations include next-gen MRI, high-resolution imaging, continuous biosensing, and AI-designed molecular tools, enabling earlier detection and more precise biological insights.

eSensorem

eSensorem is a biotech company developing a fully needle free multi-analyte biosensing patch and corresponding AI-driven platform. Our band-aid-like patch measures glucose, lactate, cortisol, pH, and hydration from less than a microlitre of resting sweat. The science is co-developed with the Terasaki Institute for Biomedical Innovation and is protected by pending patents. By offering a combination of real-time feedback, actionable insights, and a focus on user experience, eSensorem empowers individuals to take control of their metabolic health—ultimately guiding them toward a healthier, more proactive life. This groundbreaking technology is non-invasive, accessible and affordable, bypassing the obstacles faced by current wearable devices.

FISCHER IMAGING
BETTER IMAGING, BETTER OUTCOMES

Fischer imaging is focused on fixing the failings of today's mammography. Our company succeeds Fischer Imaging Corp., a company with a history of innovation having pioneered digital mammography and stereotactic biopsy. MammoCAT, our newest product, based on our patented Slot Scanning Technology, doubles the resolution and contrast of today's mammography using less than half the radiation dose in a "pain free compression" test. This will help catch cancers missed by today's mammography particularly in young women and women with dense breast tissue and reduce unnecessary testing and biopsy. This will also increase women's compliance with mammography recommendations. We have raised $3.4 M including $3.0 M in non-dilutive federal and state grants and built a clinical prototype demonstrating our performance claims with the help of Johns Hopkins University hospital, our development partners. We are now raising our first equity round (series A) of $10M to obtain regulatory approval and commercialize MammoCAT.

imaginostics

Imaginostics is creating the future gold standard in MRI by transforming imaging from pictures into biology. Our FDA Breakthrough-designated QUTE-CE MRI platform generates a new quantitative data layer that measures vascular structure, function, perfusion, and leakage with 10–100× richer detail than conventional MRI or CT. This renal-safe imaging solution addresses major unmet needs for patients who cannot receive gadolinium and for clinicians who require reproducible, site-independent physiological data. The platform integrates three products: ImagiView™, a vendor-agnostic quantitative acquisition engine; ImagiSight™, an AI analytics layer producing 8+ vascular biomarkers and digital-twin assessments; and ImagiHance™, a kidney-safe iron-based contrast agent designed to unlock quantitative signal. Together, they enable earlier disease detection, standardized multi-site imaging, and validated endpoints for clinical trials. With applications across CKD, ADRD, oncology, stroke, and TBI, Imaginostics delivers a category-defining solution that powers precision medicine, accelerates drug development, and scales across global MRI infrastructure.

MONOD BIO

Monod Bio is an AI-native protein design company co-founded by Nobel laureate David Baker. We develop next-generation biomolecular tools - including NovoBodies™ (AI-designed binders), LuxSit Pro de novo luciferases, and NovoLISA™ one-step homogeneous immunoassays - that dramatically improve sensitivity, stability, and workflow simplicity for diagnostics, life-science research, and bioprocessing. We offer a commercial catalog of more than 100 products spanning diagnostic targets, reagents, and assay kits. Our "Monod Inside" model embeds our designed proteins directly into partner instruments, assays, and consumables to enhance product performance. Monod has executed multiple agreements with leading diagnostics and life-science companies to bring novel products enabled by our technology to market. Backed by $32M in funding, we are scaling our platforms and partnerships to power the next generation of biomolecular tools for the life sciences.

JANUARY 13 | 9AM-5PM

INNOVATOR'S PITCH CHALLENGE TRACK 1

Location: Golden Gate C2

	Pitch Company			
9:00 - 9:50 AM **SESSION #12** **R&D & DIGITAL HEALTH TECHNOLOGIES** *Clinical Intelligence & Predictive Modeling Platforms*	28bio	nSight Surgical	REVIVO BioSystems	Talius
10:00 - 10:50 AM **SESSION #14** **THERAPEUTICS** *Targeted Oncology Therapies*	Biosortia	Kahr Medical	Nanogrow Biotech	QBiotics Group
11:00 - 11:50 AM **SESSION #16** **THERAPEUTICS** *Therapies for Metabolic & Immune Disorders*	CDR3 Therapeutics	IsletRegen	LORAI Health	Repair Biotechnologies
1:00 - 1:50 PM **SESSION #18** **DIAGNOSTICS** *Women's Health & Precision Health*	Adaptyx Biosciences	Ketim Technologies	Molecular You	Proseek Bio
2:00 - 2:50 PM **SESSION #19** **MEDICAL DEVICES** *Physiologic Modulation Devices*	Aurenar	Bivacor	Cool Beans Underwear	i-Lumen Scientific
3:00 - 3:50 PM **SESSION #21** **DIAGNOSTICS** *Novel Diagnostics & Clinical Decision Tools*	DetellaDx	Hemeo	Huna AI	Pharma in silica
4:00 - 4:50 PM **SESSION #23** **THERAPEUTICS** *Emerging Therapies & Targeted Interventions*	Eva Scientific	iQure Pharma	Nintx	ONCOVITA

JANUARY 13 - 9 AM | SESSION 12 - R&D & DIGITAL HEALTH TECHNOLOGIES

Clinical Intelligence & Predictive Modeling Platforms

This session features computational and experimental platforms that accelerate R&D, improve care delivery, and generate deeper predictive insights. Technologies span organoid-based modeling, autonomous surgical intelligence, in-silico prediction engines, and real-time clinical workflow decision systems.

28bio™

28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will actually work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition.

nSight Surgical

nSight Surgical has built the first artificial intelligence platform using computer vision to objectively document healthcare information. The system acts as a lean six sigma coach for OR operations and is a consistent observer reporting efficiency, quality, and cost data to health centers. nSight started as a Stanford BioDesign project, then a Stanford Hospital quality improvement project, and has now emerged as an accelerated startup by UC Berkeley Health Engine, Stanford StartX, and Stern Business School at NYU's Endless Frontier Labs. Recognition & Differentiators: 4 patents, HLTH Best-in-Class Surgical Transformation Award, UCSF DOC SF Pitch Competition Winner, Top 5 Global AI Company (SXSW Pitch), and Top 5 Global Healthcare Startup (InVentures Canada).

REVIVO BioSystems

REVIVO BioSystems provides a revolutionary preclinical 4D tissue-on-chip testing platform for ex vivo and in vitro testing the efficacy and safety of pharmaceutical, nutraceutical cosmetic ingredients, without animal experimentation. REVIVO's platform accelerates preclinical tests by pioneering a unique combination of a patented microfluidic system, innovative tissue engineered organ-on-chip models and proprietary biomarker tracking over time method. The alternative methods for preclinical research enabled by this platform address critical needs in preclinical testing and align perfectly with the latest FDA regulations encouraging pharmaceutical companies to generate data without relying on animal models.

Talius

Talius is an In Real-Time Healthcare Operating System that aggregates, analyses, and visualises IoT sensor data to deliver actionable alerts and automated workflows across hospitals, aged care, and home care. As the only platform spanning the full continuum of care - from homes to hospitals - Talius transforms fragmented inputs into clinical and operational action. It integrates a wide range of sensors including vital signs, falls, sleep, medication adherence, and location tracking. Through a single interface, Talius empowers providers to act immediately, improve outcomes, reduce risk, and deliver compliant, accountable care. With over 50,000 subscribers, $3.5M in ARR, and $30M in lifetime sales, Talius is enabling care teams across Asia-Pacific to shift from reactive to proactive care.

JANUARY 13 - 10 AM | SESSION 14 - THERAPEUTICS

Targeted Oncology Therapies

This session showcases next-generation oncology therapeutics built to overcome limitations of current treatments. Companies provide multi-pathway immunotherapies, tumor-selective payload delivery, interventional oncology approaches, and nature-derived small molecules backed by strong scientific rationale.

Transforming Discovery and Derisking Development High-Impact Pipeline: Biosortia is targeting massive, unmet medical needs with a first-in-class portfolio. This includes a novel weight loss portfolio, a non-opioid pain solution (both local and systemic), and a groundbreaking approach to anxiety and depression targeting the gut-brain axis—tapping into a projected $180 billion annual market. Disruptive Economics: Industry average requires 40 programs to achieve a single approval for synthetics, Biosortia projects a success rate of 2 programs per approval. This translates to faster speed-to-market and significantly lower capital costs. Unmatched Technology Stack: Our competitive moat is built on superior breakthrough technology that combines vast proprietary datasets with advanced AI training. This ""Computational Stack"" allows us to see what others miss. Proven Leadership: Led by Ross Youngs, a successful serial entrepreneur and technology builder. The leadership strategy focuses on orchestration—leveraging elite internal capabilities alongside best-in-class external expertise to accelerate milestones and maximize ROI.

KAHR develops novel, dual-targeting fusion protein therapeutics engineered to activate both the innate and adaptive immune systems simultaneously and localize that response in the tumor microenvironment. The company's lead compound, DSP107, has demonstrated superior efficacy and safety in combination with atezolizumab as compared to available therapies in late line, microsatellite stable metastatic colorectal cancer (MSS CRC), a market opportunity of greater than $1bn in annual sales. The American Society of Clinical Oncologists invited KAHR to present its data in a prestigious oral presentation at ASCO 2025. KAHR completed a $22mm raise in October 2025 which will fund a phase 2b trial of DSP107 in late line MSS CRC patients. KAHR is seeking additional investment in a deferred close of up to $10mm.

Nanogrow Biotech is developing a new generation of biological products based on camelid-derived nanobodies, for the treatment of cancer and immune disorders. Traditional antibody treatments face challenges of accessibility, due to their high costs and focus on severe cases only, and systemic toxicity, caused by their non-localized administration. To address these limitations, Nanogrow is developing therapies that combine the efficacy of antibody-based treatments with localized delivery specific to each disease, enabling safer, effective, and more accessible treatments. Its bioengineering platform integrates natural and synthetic nanobody libraries with computational design and molecular fusion technologies to generate targeted candidates for each indication. With a multi-product pipeline, Nanogrow develops and co-develops assets with pharmaceutical partners. Its B2B model captures value at each milestone, combining short-term revenue from less-regulated markets with long-term value creation from high-impact therapeutics—building a scalable path toward next-generation immunotherapies with strong clinical and commercial potential.

QBiotics is an Australian clinical-stage life sciences company developing small molecule therapeutics derived from nature, targeting oncology and wound healing – both markets with high unmet medical need. The Company's proprietary EcoLogic™ biodiscovery platform systematically identifies and scales plant-derived small molecules, generating first-in-class pharmaceutical assets with lower development risk than conventional target-based discovery models. QBiotics' lead asset is tigilanol tiglate -an interventional oncology asset (intra-tumoral therapy) now advancing through Phase II trials for indications with high unmet medical needs: Soft Tissue Sarcoma (STS) and head and neck cancer. As a member of an emerging category of interventional therapies, tigilanol tiglate demonstrates a less toxic, tumor-targeted approach to cancer management.QBiotics' second asset EBC-1013 is in a Phase I trial assessing its safety and tolerability in patients with venous leg ulcers, with the broader potential to treat a range of advanced chronic and acute wounds.

JANUARY 13 - 11 AM | SESSION 16 - THERAPEUTICS

Therapies for Metabolic & Immune Disorders

Showcasing therapeutics that address dysregulated metabolism, autoimmune conditions, and hormonal pathways, this session emphasizes targeted delivery systems, immune-modifying mechanisms, and endocrine restoration. Collectively, these companies aim to reverse or stabilize complex systemic disorders.

CDR3 Therapeutics

In the fight against leukemia and lymphoma, T cells are a powerful tool. But, while modifying a human immune system through gene therapy to fight viruses and cancers is a hopeful direction, it hasn't yet become a reality for most diseases. That's because current technologies have short-lived effects. Which is why we developed CDR3's unique, patented technology, which uses stem cells to build long-lasting immunity against viruses and cancers — creating a self-renewing source of gene-targeted immune cells in the body. It connects a much-needed therapy to the lives of people who need it. And it leverages the power of the human immune system by harnessing the power of stem cells. While this revolutionary new solution for cancer treatment is here, we need you to make it possible. Through your investment in CDR3, you'll see pain begin to disappear, lives start to improve, and your portfolio produce a return – all while helping humanity in a positive new direction.

IsletRegen, LLC ('IsletRegen') is a Virginia-based company developing first-in-class dual immunomodulatory and regenerative therapeutics for a broad range of autoimmune diseases, including Type 1 diabetes, lupus, rheumatoid arthritis, and alzheimers, amongst others. The company's initial focus is on early-stage 1 diabetes. The drug is RegenPepTM, a synthetic mimetic replacement therapy for human plasma lacritin deficiency. RegenPep blocks early development of autoimmunity and restores natural insulin production by combining T, B cell depletion with -cell regeneration.

LORAI

LORAI Health is building the next-generation global transdermal drug-delivery platform—combining advanced polymers, structured reservoirs, and bio-adhesives to enable precise, skin-friendly, and reliable delivery of complex drugs. Our first proof-of-concept (Gen-1) patch is deeply personal and strategically opportunistic: rapidly solving Australia's ongoing menopause hormone therapy (MHT) patch shortages that affect more than 5M Australian women in midlife. Beyond the Australian MHT patch, LORAI is targeting next-generation patch for delivery of MHT as well as high-value CNS and pain drugs.

Repair Biotechnologies

Repair Biotechnologies' platform technology enables rapid clearance of excess intracellular free cholesterol, an undruggable target that contributes to the pathology of many age-related and obesity-related conditions - including atherosclerotic cardiovascular disease. Atherosclerotic plaque remains the primary cause of human mortality and existing therapies do all too little to prevent this outcome. We can change that situation. Our lead drug produces dramatic, rapid regression of arterial plaque in preclinical models of atherosclerosis and familial hypercholesterolemia, making it the first potentially curative therapy for atherosclerotic cardiovascular disease.

JANUARY 12 - 1 PM | SESSION 18 - DIAGNOSTICS

Women's Health & Precision Health

This session highlights diagnostics and biosensing platforms tailored to women's health and personalized care. Companies apply multi-omics analysis, protein biomarkers, AI-based risk scoring, and continuous biosensing to advance early detection, reproductive health insights, and metabolic precision monitoring.

Adaptyx Biosciences, a Stanford University spin-off, is building a biomonitoring platform that leverages 15 years of research in molecular switches and microarray patches, enabling minimally-invasive real-time, continuous sensing of small molecules and proteins. Adaptyx's library of multi-analyte sensors will enable deeply personalized medicine across drug dosing, hormone regulation, kidney health, cardiovascular disease, and oncology.

Ketim Technologies' AI-based risk scoring system transforms complex proteomic data into clinically actionable insights. Using advanced machine learning models trained on thousands of plasma and PBMC-derived protein profiles, the algorithm calculates a Maternal Predictive Risk Score (MPRS) that correlates strongly with Edinburgh Postnatal Depression Scale (EPDS) scores ($r = 0.91$; AUC = 0.94). The model integrates biological, psychosocial, and demographic inputs to identify subtle biomarker patterns linked to stress, inflammation, and neuroendocrine dysregulation—long before symptoms appear. Designed for clinical integration, the AI engine delivers an interpretable risk output, categorizing mothers into low, moderate, or high risk for postpartum depression. This data-driven approach enables early intervention and personalized care, paving the way for scalable, evidence-based mental health screening in obstetric and primary care settings.

Molecular You measures over 250 biomarkers with a single blood test using advanced proteomics and metabolomics to identify health risks at their root cause. Its AI-powered platform delivers personalized assessments and insights, along with actionable recommendations for over 25 health areas, to support longevity, chronic disease management, and early disease prevention. Both individuals and clinical practices across the United States and Canada are increasingly leveraging Molecular You to maximize personal and patient health outcomes through predictive, preventive, and precision medicine. Learn more: https://www.molecularyou.com/

Executive Summary:

- Proseek Bio is an early-stage diagnostic company developing first-in-class mass spectrometry-based glycoprotein biomarker panel blood tests for women's health, starting with ovarian cancer.
- Its LeMBA-MS platform integrates a patented biomarker assay, reagent kit, and algorithm to deliver actionable diagnostic scores using existing lab infrastructure.
- Initial OC-Triage validation achieved 100% sensitivity and 79% specificity, exceeding the benchmarks of existing commercial tests.
- The company is launching through clinical pathology lab partners under LDT pathways to accelerate market entry while preparing for IVD approvals
- With a robust IP portfolio and an experienced team, Proseek is positioned to scale globally and deliver significant clinical impact and commercial value.

Market Opportunity/Unmet Need:

- Ovarian cancer is often diagnosed late due to vague symptoms and lack of effective early detection tools
- The global ovarian cancer diagnostics market is valued at US$4.6B and growing

JANUARY 13 - 2 PM | SESSION 19 - MEDICAL DEVICES

Physiologic Modulation Devices

This session explores devices that modulate physiological systems for therapeutic benefit, including neuromodulation, cardiac support, vision restoration, and men's reproductive health. These technologies offer highly differentiated, often non-pharmacologic approaches to restoring normal physiological function.

AURENAR

Aurenar is on path to achieve tremendous health and economic impact by addressing inflammation - the underlying cause of life-threatening and costly complications in the ICU. Our ear-worn device boosts the body's natural control of inflammation by activating a nerve located in the ear with imperceptible and non-invasive stimulation. Our approach has been successfully demonstrated in multiple randomized controlled clinical pilot studies, showing: improved patient outcomes, reduced hospital length of stay, and lower cost of care.

BiVACOR®

BiVACOR® is a clinical-stage medical device company pioneering the development of a long-term therapy for patients with biventricular heart failure. Under the expert direction of its founder and TAH inventor, Daniel Timms, PhD, and the guidance of two luminaries in cardiovascular surgery, William E. Cohn, MD, and O.H. (Bud) Frazier, MD, the BiVACOR TAH is currently undergoing an FDA-approved first-in-human Early Feasibility Study (EFS). Headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices in Gold Coast, Australia, BiVACOR is committed to addressing the global unmet need of patients with end-stage heart failure awaiting transplant by providing the next generation of life-extending solutions.

COOLBEANS® MEN'S HEALTH UNDERWEAR

Coo lBeans is an early revenue generating company: the world's first & only registered medical device underwear, engineered to reduce testicular heat. Testicular heat is a clinically validated yet long-overlooked driver of male infertility, hormone imbalance, and poor recovery outcomes and more. Our patented external mesh pouch design gently elevates & repositions the scrotum to prevent the insulating effect of the thighs & keep the scrotum away from core body heat – enabling optimal testicular temperatures. With granted IP across 20+ countries, and growing demand across fertility, oncology, & sports recovery, Cool Beans is uniquely positioned to lead a new category of wearable device. We are currently planning impact trials in Brisbane with the University of Queensland. While we know with certainty that our device has physiological impact, the size of that effect and its ripple across broader men's health and future generational outcomes, remains a critical area of discovery with significant upside.

i-Lumen Scientific™ ADVANCING VISION RESTORATION

i-Lumen Scientific has developed an Ocular Stimulation Therapy to improve vision in those with intermediate and advanced Age-related Macular Degeneration. AMD is the leading cause of blindness in those over age 55. It leads to loss of the central field of vision. i-Lumen's AMD System® is an office-based therapy that uses proprietary neurostimulation that is delivered via electrodes applied to the surface of the eyelids. The therapy improves function and restores structure of the retinal pigment epithelium (RPE) and Photoreceptor Cells. i-Lumen's US-based, multicenter, randomized controlled study (i-SIGHT Study) completed in June 2025 demonstrated that 61.5% of participants treated with i-Lumen had a 10 letter or 2 lines of improvement in visual acuity after just 7 treatment sessions delivered within 2 months. i-Lumen projects commercialization in the first half of 2028 following the completion of its Pivotal Study, the i-SIGHT2 Study, and FDA clearance via a De Novo submission."

JANUARY 13 - 3 PM | SESSION 21 - DIAGNOSTICS

Novel Diagnostics & Clincial Decision Tools

This session highlights next-generation diagnostic technologies and clinical decision tools designed to deliver faster, more actionable insights at the point of care. Companies are leveraging AI, advanced data analytics, and novel biomarker approaches to improve early detection, risk stratification, and clinical decision-making across a range of disease areas.

DetellaDx is developing a breakthrough early detection technology to diagnose ovarian cancer at Stage I, when the disease is still highly treatable. Using a proprietary single-cell approach combined with AI/ML-driven next-generation sequencing, DetellaDx enables highly accurate detection of cancer at its earliest stages. The technology originated at the University of Washington, supported by NIH-funded research, and is now advancing toward commercialization. DetellaDx's initial focus is a CLIA laboratory-developed test for women with high genetic risk of ovarian cancer, addressing a critical unmet need where no reliable early screening exists. Ovarian cancer is often asymptomatic and diagnosed late, leading to poor outcomes. By enabling earlier diagnosis, DetellaDx aims to dramatically improve survival, provide peace of mind, and transform ovarian cancer care.

We build Clinical Support System predicting coagulation problems. Our A.I. powered technology enables earlier and personalised therapies. Our algorithms have been trained and verified against a +5,000 clinical patient database. We are currently building research collaboration with leading academic centres around the world to validate our algorithms and our coagulation model. Our company is based in The Netherlands where we benefit from a rich ecosystem with our partnerships with NLC, the European Healthtech Venture Builder, and with Philips where our core technology was originally developed.

We are Huna, a deeptech company making early-cancer detection affordable for 99% of the world leveraging the power of routine blood tests with cutting-edge artificial intelligence. By partnering with leading cancer centers and labs, we're building algorithms with one of the largest and most diverse datasets in the world (+ 5 million patients). We are on a mission to re-shape the healthcare system by improving access and reducing inequalities in cancer care.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Its mission is to improve quality of life and survival for patients undergoing chemotherapy, beginning with solid tumors. The company aims to commercialize a universal, safe, and affordable precision chemotherapy in partnership with major pharmaceutical companies by 2027.

Conventional chemotherapy often delivers limited survival benefits while disrupting the immune system and causing severe, long-lasting side effects such as anemia, infections, and neurological disorders. Despite generating more than $17 billion in annual sales, chemotherapy remains one of the least-studied areas in oncology, with few trials focused on safety and effectiveness.

Pharma in silica is developing a proprietary silica nanocarrier that circulates safely in the bloodstream without impairing blood cell function and delivers high concentrations of cytotoxic agents directly to tumors. This targeted approach is expected to enhance efficacy while significantly reducing side effects.

In July 2025, the company launched an open call inviting the scientific community to contribute innovations to its Precision Chemotherapy™ platform.

JANUARY 13 - 4 PM | SESSION 23 - THERAPEUTICS

Emerging Therapies & Targeted Interventions

This session features emerging therapeutic approaches focused on targeted, mechanism-driven interventions for complex and high-unmet-need conditions. Companies are advancing novel modalities and precision strategies designed to improve efficacy, reduce systemic burden, and deliver differentiated clinical outcomes across oncology and other serious diseases.

Eva Scientific is a biotechnology company specializing in tissue engineering, focused on the production of collagen, engineered tissues, and bioartificial organs. Ranked #1 in the 100 Open Startups Ranking within the "Top 5 Biotech" category, Eva is recognized as an authority in collagen science, bioreactors, and laboratory-created organs. Founded in 2015 by tissue engineer Andreas Kaasi, the company was established with the ambition to save lives through innovative medical devices and research tools that enable academic and industrial researchers to achieve more with fewer resources. Eva's first commercial products are built on more than a decade of expertise in collagen—the fundamental structural component of tissue when combined with cells—alongside advanced bioreactor systems that function independently or integrate seamlessly with its biofabrication platforms. Eva Scientific's work is supported by the São Paulo State Research Foundation (FAPESP, Grant 2014/22799-3). The company is committed to driving impact, innovation, and transformation toward improved health, longevity, and quality of life.

iQure is a clinical-stage biotech pioneering a novel approach to CNS diseases by targeting a core driver of neuronal damage: impaired glutamate clearance. Our lead asset, iQ-007, is the first EAAT2-positive allosteric modulator in clinical development, restoring astrocytic function to break the cycle of excitotoxicity. iQ-007 is at the Phase 1 completion and already raised significant market traction in global pharma. iQ-007 lead indication is epilepsy inc. Drug Resistant Epilepsy with option to expand toward treatment of migraine and Parkinson's Disease.

Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies with environmental and social impact. To that end, Nintx has established partnerships with research institutes, private companies and investment funds that bring both complementary expertise and financial resources. Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil, targeting multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Nintx owns cutting-edge proprietary technologies, an Agentic AI platform (GAIApath®) and an artificial gut (xGIbiomics®), that enable the development of innovative ingredients (pharmaceuticals and nutraceuticals).

Oncovita is a pre-IND/CTA-stage biotech company based in Paris and a spin-off from the Institut Pasteur. We are developing MVdeltaC, a next-generation oncolytic immunotherapy lead product based on genetically modified measles vaccine strains. This approach offers a strong safety profile and targeted immune-mediated tumor destruction. MVdeltaC, is expected to enter a First-in-Human Phase I trial in 2026, both as monotherapy and in combination with an immune checkpoint inhibitor. A Phase IIa study will follow, targeting Pleural Mesothelioma (for which we received in June the Orphan Drug Designation from the FDA) and Triple-Negative Breast Cancer. We have generated robust preclinical data, a promising case report, and benefit from scientific backing from the Institut Pasteur—all of which reinforce the potential of our platform and its favorable risk profile.

JANUARY 13 | 9AM-5PM

INNOVATOR'S PITCH CHALLENGE TRACK 2

Location: Golden Gate C3

	Pitch Company			
9:00 - 9:50 AM **SESSION #13** **DIAGNOSTICS** *AI-Enabled Imaging & Multi-Omics Diagnostics*	KYAN Technologies	MiRNDa	Rosalind Dx	STARCO
10:00 - 10:50 AM **SESSION #15** **MEDICAL DEVICES** *Chronic Disease & Functional Monitoring*	Aptium AI	Blend Health Technologies	DARWIN Biomed	Orange Biomed
11:00 - 11:50 AM **SESSION #17** **THERAPEUTICS** *Novel Approaches to Restore Biological Function*	Animate Biosciences	Fibrosoft	HOPO Therapeutics	Retroviral Proviromics
2:00 - 2:50 PM **SESSION #20** **R&D & LIFE SCIENCE TOOLS** *Biomanufacturing & Biologics Innovation*	ChemT Biotechnology	Dyogel	Great Bay Bio	Multus Biotechnology
3:00 - 3:50 AM **SESSION #22** **R&D AND LIFE SCIENCE TOOLS** *Enabling Platforms for Therapeutic Development*	BASH	Biolinker	CNPen	Gen-T
4:00 - 4:50 PM **SESSION #24** **DEVICES & DIGITAL HEALTH** *Advancing Clinical Care Delivery*	CygnusMed	Kilele Health	Orby	Telavita

JANUARY 13 - 9 AM | SESSION 13 - DIAGNOSTICS

AI-Enabled Imaging & Multi-Omics Diagnostics

Highlighting AI-accelerated diagnostic solutions, this session includes precision oncology tools, RNA-modification–based cancer screening, multi-omics biomarker platforms, and spatial AI pathology. These technologies represent major advances in early detection, risk stratification, and clinical decision support.

KYAN TECHNOLOGIES

Optim.AI™, a functional precision medicine platform, combines small data AI with biological experiments to analyze the functional response of drug-dose combinations. The high heterogeneity of cancer tumors complicates the search of combinations that can help reduce drug resistance. Optim.AI™ can identify optimal drug-dose combinations across different mechanisms of action regardless of the nature and stage of disease and has been applied at multiple stages in drug development. The clinical validation of Optim.AI™ has been demonstrated across more than 20 cancer types across hematological and solid cancers with an overall clinical accuracy of 82%. Optim.AI™ has been approved as a commercial, laboratory-developed test by the Ministry of Health Singapore (MOH). the KYAN laboratories have also been accredited by the College of American Pathologists (CAP) and certified according to ISO 13486 and is in process of becoming CLIA validated in the USA through a collaboration with Mayo Clinic Laboratories."

MiRNDa

MiRNDa, is a startup dedicated to creating a world where cancer can be cured through the social implementation of cancer screening based on our proprietary RNA modification technology. Many cancers, such as pancreatic and liver cancer, are known as "silent killers" because they are difficult to detect at an early stage. Early detection is therefore the most critical factor in improving patient outcomes. Through our research, we have discovered that RNA modifications occur even at the earliest stages of cancer development. This breakthrough enables highly accurate early cancer detection. We are now advancing both product development and business development to bring our screening technology into routine clinical practice—starting with pancreatic cancer, which currently has one of the lowest 5-year survival rates. Our goal is to deliver innovative screening services that address cancers with high unmet medical needs and contribute to saving lives worldwide.

ROSALIND DX
PRENATAL TESTING FOR ALL

Rosalind Dx is making prenatal testing accessible to all expecting parents. Today, detecting fetal abnormalities requires expensive send-out testing, creating socioeconomic barriers that delay critical care decisions. Our solution is a PCR-based workflow that enables any CLIA lab to run NIPT in-house. Our proprietary technology delivers results in 2 days versus 10, at half the operational cost of sequencing platforms. Labs can finally capture margins currently lost to centralized labs, and generate NIPT revenue for the first time. Our team brings decades of prenatal testing expertise, including launching PerkinElmer's Vanadis NIPT platform and 10+ other IVDs. Our unique insights informed our patent portfolio and GTM strategy: RUO kits enabling seamless LDT validation. We've secured a validation partnership with an industry-leading reference lab. We're raising $1M seed to complete preclinical validation and reach early clinical validation within 12 months. $500K in soft commitments secured.

STARCO

STARCO is building a proprietary spatial-AI platform redefining precision pathology. By integrating spatial statistics, deep learning, and spatial transcriptomics, STARCO transforms traditional histopathology into a multimodal, explainable system for cancer diagnostics, prognosis, and treatment guidance. Its lead precision-pathology program targets early-stage cancers where improved diagnostic certainty and predictive insights can directly inform patient monitoring and therapy decisions. The platform's clinically interpretable outputs deliver both visual and quantitative clarity, reducing diagnostic delays and enhancing treatment precision. Powered by a proprietary dataset of over 20 million annotated cancer cells and an advanced agentic multimodal AI engine, STARCO is positioned to partner with MedTech and pharma companies across clinical diagnostics, trial enrichment, and biomarker discovery. The company is seeking $12 million to scale commercialization and expand its multi-market precision oncology applications.

JANUARY 13 - 10 AM | SESSION 15 - MEDICAL DEVICES

Chronic Disease & Functional Monitoring

This session highlights devices that continuously monitor physiological states including cardiovascular, neurologic, respiratory, and metabolic function. Using advanced sensors, imaging, and AI modeling, these companies enable earlier intervention and more personalized chronic disease management.

Aptium Pty Ltd is commercializing a patented 3D/4D scanning and thermal imaging technology integrated with advanced AI analytics.

- Aptium's flagship products; MotionScan4D™, MultiScan4D™, and ThermalScan4D™ — enable instantaneous high-resolution static and motion scanning for applications spanning podiatry, diabetic foot ulcer detection, sports medicine, human movement studies and a wide range of other healthcare and industrial applications.
- Aptium's initial target market is focused on the US $4.8B podiatry market and the rapidly expanding diabetes-related foot ulcer (DFU) diagnostic space valued at US$8.8B
- Aptium will offer podiatry offering clinics a "one-stop shop" to scan, model, and 3D print customized orthotics in addition to assisting in the early diagnosis and intervention of diabetes related foot ulcers.

Blend Health Technologies,, a company transforming hypertension management, is bringing the world proactive healthcare. Its cuffless upper-arm wearable for accurate ambulatory, remote and continuous blood pressure monitoring captures critical trends and variability over time to drive precision medicine for healthcare professionals and deliver better outcomes for patients. Using the company's novel technology, healthcare providers can improve patient care and access while meeting regulatory, security and privacy requirements. Powered by deep learning and AI analytics, Blend Health Technologies provides actionable insights to enable early detection of cardiovascular risk and other chronic diseases.

We are a European company working in new generation robotics and we have created MICHELANGELO, an intelligent walker for fall prevention. In addition, all the user data is used for real-time monitoring, motor function assessment and long-term evaluation of physical evolution. We are on a pre-market stage with the first batch of 15 units already sold and focused on getting CE certification in late 2026. We are looking for USD 5M to scale up production, open an operational office in the US and obtain FDA approval by late 2027.

Orange Biomed is transforming diabetes management with the world's first at-home A1C test powered by proprietary microfluidics technology. Unlike conventional protein-based lab tests, our innovation analyzes thousands of red blood cells within minutes to deliver lab-grade A1C results anytime, anywhere. Today, more than 40 million Americans live with diabetes, yet over 90% fail to test their A1C as often as guidelines recommend. Limited access delays treatment adjustments and fuels costly complications. Orange Biomed eliminates these barriers—allowing patients to check their A1C as easily as they check their glucose, empowering earlier intervention and greater self-management. By partnering with telehealth providers, community health centers, and pharmacies, we're redefining how diabetes is monitored and controlled. Our mission is clear: make high-quality A1C testing accessible, affordable, and life-changing for millions worldwide."

JANUARY 13 - 11 AM | SESSION 17 - THERAPEUTICS

Novel Approaches to Restore Biological Function

This session features novel therapeutic platforms designed to restore lost or impaired biological function. Strategies include regenerative peptides, anti-fibrotic therapies, and advanced detoxification agents for heavy metal exposure. Despite varied indications, each solution is focused on reversing underlying biological dysfunction.

Animate Biosciences is a biotechnology company pioneering AI-designed peptides inspired by regenerative biology to treat chronic inflammation and fibrosis across multiple organs. By integrating machine learning, protein design, and insights from naturally regenerative species, Animate identifies short, multifunctional peptides capable of restoring healthy tissue architecture and immune balance. Its lead program, MBb32, targets interstitial lung disease through local, lung-directed delivery to suppress myofibroblast activation and remodel fibrotic tissue. The company's platform enables rapid peptide discovery, optimization, and validation across organ systems, creating a pipeline of disease-modifying candidates that address the fundamental drivers of aging and degeneration. Through this convergence of AI, regenerative biology, and translational science, Animate aims to extend and improve healthy human lifespan.

Fibrosoft is an Australian biotechnology company focused on developing non-surgical therapeutics for fibrotic connective tissue disorders, primarily targeting Dupuytren's disease (DD), which affects up to 30% of men over 60. The company aims for expedited regulatory approval via the 505(b)(2) pathway by utilizing existing safety data. Fibrosoft's patents, secured under PCT/AU2022/051003, are protected in the US, EU, and Australia, expiring in 2042. The platform technology also addresses related conditions like Ledderhose's disease and Peyronie's disease, presenting a substantial global market opportunity. Founded by Dr. David Chin, a Dean's List PhD surgeon-scientist, has treated over 200 patients with encouraging results. Surgery remains the standard treatment for DD, the only available pharmaceutical option, Xiaflex®, is expensive and carries numerous side effects. Fibrosoft is seeking $20-25 million to support Phase 1b studies in Australia and internationally, with plans for a pivotal study to obtain marketing approval and consider an IPO or trade sale.

HOPO Therapeutics is a clinical-stage pharmaceutical company developing best-in-class therapeutics designed to prevent and treat the toxic effects of heavy metal exposure on human health. We are addressing the urgent need for safer, more effective solutions for heavy metal toxicity. Our orally-administered chelating agents are designed to simplify treatment for patients exposed to radioactive materials like uranium and plutonium, as well as environmental toxins such as lead, mercury, and other heavy metals.

Retroviral Proviromics is creating a toolbox of monoclonal antibodies that can detect and target the aberrant expression of Human Endogenous Retroviral (HERV) proteins within the HERV-W family. This may enable earlier screening for preeclampsia, early onset T1D and certain cancers, which can be (in the case of oncology and autoimmunity) specifically targeted, utilizing a range of therapeutic modalities depending on the diseases.

JANUARY 13 - 2 PM | SESSION 20 - R&D & LIFE SCIENCE TOOLS

Biomanufacturing & Biologics Innovation

Featuring enabling technologies that improve biologics development, manufacturing scalability, and molecular stability. Companies apply AI, automation, and novel formulation systems to enhance cell line engineering, protein manufacturability, and stability under real-world conditions.

Chemt Biotechnology is a Singapore-based biotech company pioneering AI-driven cellular control to revolutionize biologics manufacturing and cell therapy. Its proprietary Virtual Cell Platform (Celmo™) digitizes cells and designs novel cell-modulating small molecules, enabling precise, tunable manipulation of cell behavior across T cells, CHO cells, and other types used in therapy and production. Chemt's flagship product, Chemplify™, boosts T cell expansion and quality up to 10×, significantly cutting therapeutic manufacturing costs and timelines. The company operates through a hybrid SaaS and licensing model, combining recurring software revenue with small molecule-based royalties. Built by a world-class team from MIT, NUS, and leading pharma firms, Chemt has secured over 20 global partnerships, including Thermo Fisher, Cytiva, Carsgen, and Evonik. By uniting AI, omics data, and wet-lab integration, Chemt delivers scalable, high-impact solutions that enhance biologics productivity and make advanced therapies more accessible worldwide.

Dyogel is a stabilisation gel that prevents protein aggregation and enables ambient storage of therapeutic proteins — eliminating cold chain dependence. Developed with the University of Glasgow and partners, Dyogel preserves protein structure against heat and agitation, delivering pure injectable biologics. The technology targets the $823 bn biologics market, addressing stability challenges across monoclonal antibodies, vaccines, insulin, botulinum toxins, enzymes and GLP-1s. Dyogel offers two key opportunities: Post market reformulation for product lifecycle extension and commodity product stabilisation for low-cost access in LMICs. IP: GB2633392A / WO2025052144 www.dyogel.com Contact: Dr Wes Randle & Dr Libby Marshall

Founded in 2019, Great Bay Bio (GBB) is a biotech innovator leveraging AI to enhance bioprocessing, addressing major challenges such as high costs, lengthy timelines, and low success rates in drug development and related sectors such as Synthetic Biology. GBB has developed advanced platforms like AlfaCell®, for site-specific stable cell line development, and AlfaMedX®/AlfaOPA®, for superior cell culture media development/optimization, as well as AlfaDAX, a protein developability and manufacturability optimization platform. The company holds over 70 patents, and established more than 40 partnerships globally. GBB has raised over $35 million across four financing rounds from top institutional investors (e.g., Hillhouse) and corporate investors (e.g., Top Global Life Science Tool company) and received recognition from Nvidia and HKSTP for its innovation. With a seasoned team experienced in IND filings in both China and the U.S., GBB is poised for significant impact in the biopharma and AI fields.

Multus Biotechnology is a global leader in cell culture media design, helping biotech companies shorten their time to market while improving product quality and supply chain security. By combining high-throughput robotic automation, proprietary real-world datasets and AI, Multus revolutionizes cell culture media development - delivering breakthrough performance and efficiency that were previously unattainable. Multus' experienced, multi-disciplinary team of scientists and engineers is redefining the future of biopharmaceutical manufacturing. Harnessing the power of biology, automation, and machine learning, we accelerate the creation of high-performance, resource-efficient cell culture media, enabling the next generation of essential therapies.

JANUARY 13 - 3 PM | SESSION 22 - R&D AND LIFE SCIENCE TOOLS

Enabling Platforms for Therapeutic Development

This session showcases platform companies building the foundational technologies that accelerate therapeutic discovery, development, and translation. Presenting companies offer enabling tools that improve biological modeling, target validation, and experimental efficiency, supporting more predictive and scalable therapeutic innovation across multiple modalities.

BASH

BASH is a biotechnology company dedicated to advancing human health and well-being through cutting-edge scientific innovation. We develop advanced products, treatments, and solutions by harnessing breakthroughs in biotechnology, tissue engineering, and materials science. By integrating these disciplines, we move beyond traditional approaches to deliver transformative, next-generation healthcare solutions. Driven by innovation, ethics, and scientific excellence, BASH is committed to sustainability, safety, and social responsibility. Our work is guided by a vision to create a healthier future while preserving the environment and earning public trust. We foster collaboration and embrace diversity, building an inclusive culture that inspires discovery, accelerates progress, and redefines what is possible in biotechnology.

BIO LINKER

We are a biotechnology and synthetic biology startup created by scientists for scientists. We act as a service provider and developer of innovative solutions and kits for research and industrial activities involving protein use, bringing practicality and agility to laboratory work. We work using cell-free expression system technology (CFPS), a fast, simple, high quality, and assertive solution for protein expression and purification, which can be applied in various scientific and industrial segments. We provide a proactive service and we are always available to answer any questions regarding our technology, products, and services. To learn more about BioLinker, our activities, and concepts, visit our website, follow us on social media or contact one of our representatives. We look forward to assist you in the development of your projects!

CNPEM
Brazilian Center for Research in Energy and Materials

The Brazilian Center for Research in Energy and Materials (CNPEM) is a unique, world-class research and development environment and one of only a few of its kind globally. A private, non-profit organization overseen by Brazil's Ministry of Science, Technology, and Innovation (MCTI), CNPEM operates four national laboratories and hosts Sirius, one of the world's most advanced synchrotron light sources and the most complex scientific project in Brazil. CNPEM brings together highly specialized, multidisciplinary teams and globally competitive laboratory infrastructure open to the scientific community. Its research drives impactful solutions in health, energy and renewable materials, agroenvironmental sciences, and quantum technologies, while fostering innovation through partnerships with industry. In 2022, CNPEM expanded its mission with the launch of the Ilum School of Science, a free, full-time interdisciplinary undergraduate program embedded within its research ecosystem.

gen-t

We are a company formed by the union of nonconformists. On the one hand, scientists who seek to discover who Brazilians really are and, on the other hand, entrepreneurs and investors who understand the value of this discovery for the country. While other countries in the world are advancing in the sequencing of the DNA of their population, Brazil is still behind. Traditional paths to the evolution of science do not advance. And we are the ones who lose out, because important traits that may be hidden in our genome are no longer identified, putting Brazilians outside the so-called precision medicine. Gen-t was created to be a platform capable of including Brazil on the map of genomic research. Understanding our origins is the only path to full development. Knowing our identity, we will be able to develop more effective medicines and treatments for our diseases and verify that Brazil is, in fact, one of the countries with the greatest genetic diversity in the world.

JANUARY 13 - 4 PM | SESSION 24 - DEVICES & DIGITAL HEALTH

Advancing Clinical Care Delivery

This session brings together innovative device and digital health companies focused on improving real-world clinical care delivery. Presenters offer technologies that enhance procedural safety, optimize clinical workflows, and support better decision-making in acute and routine care settings, bridging the gap between innovation and everyday clinical practice.

Cygnus device allows the performance of all endovascular interventions and offers continuous arterial blood pressure measurement through a single artery access while further decreasing blood loss. Thus eliminating the current practice of a second arterial access during Neuro and peripheral endovascular interventions.

Kilele Health will be the sole provider of wearable blood chemistry sensors that combine longevity (lasts 10+ days) with variety (can measure many biomarkers or drugs). Our SunVida system, protected by 50+ pending patents, will migrate chronic disease management from crisis-based care to status-based care by giving patients and care teams actionable real-time data, preventing crisis & improving outcomes while dramatically reducing costs. The sensor mimics the proven form factor of continuous glucose monitors - a small painless device worn on the arm or abdomen. Kilele has 3 applications in development: phenylalanine (Phe) to manage pediatric phenylketonuria (prevent permanent cognitive damage), NT-proBNP, potassium (K), and creatinine (Cre) to manage heart failure (prevent hospital readmissions, a $16B problem), and Phe, K, Cre, and lactate to manage the most intense multi-chronic patients with an early warning (shift care from ER and hospital to clinic, a 10% shift = $100B savings).

We're building intelligent systems that connect directly to the human nervous system, not with implants, but with real-time adaptive neuromodulation that teaches the brain to heal itself. Our technology decodes physiological signals to deliver precise, personalized stimulation. It's an AI that learns from the body and speaks the nervous system's language to restore lost functions, relieve pain, and expand human capability. No surgery. No limits. Just science, AI, Hardware, and a vision for what's possible. Orby isn't just a medical platform. It's a new frontier: the beginning of a world where machines don't just respond to humans… they understand us from within. We are proud to be backed by giants like @Google, @NVIDIA, and @Microsoft. And we're just getting started. This is not a device. This is evolution. We're not just treating symptoms, we're reprogramming how the body heals and moves, redefining the global standard for neurorehabilitation.

Telavita has a populational map methodology through an emotional health self-evaluation. Considering each given answer, each beneficiary gets a personalized journey of coordinated care, with educational content, guided exercises, therapeutic chatbot, care navigation, and/or psychology and psychiatry online therapy sessions.

JANUARY 12 - WORKSHOPS & GLOBAL INNOVATION SHOWCASE

Location: Golden Gate B

9 AM | NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS

A Breakthrough Framework for Smarter Life Science Investing

10 AM | THE FAST LANE TO POC

Leveraging Australia and China for Smarter Early Clinical Development

Early-stage biotechs need fast, high-quality data to attract investment. This workshop shows how Novotech accelerates First-in-Human and early Proof-of-Concept by leveraging Australia's rapid start-up environment and China's patient-rich ecosystem, delivering an integrated, timeline-compressing early development strategy investors value.

11 AM | VENTURE VALUATION WORKSHOP

Company Valuation for Fundraising

Valuation is central to fundraising, and stage-based averages no longer suffice. This session explores recent financing trends, key value drivers for life science companies, dos and don'ts in investor discussions, and practical approaches to valuing pre-revenue life science companies.

12 PM | CONDUCTING CLINICAL TRIALS IN AUSTRALIA POWERED BY QUEENSLAND GOVERNMENT

Location: Golden Gate C3

1 PM | GLOBAL INNOVATION ACCELERATOR & PORTFOLIO SHOWCASE

Introducing NISA Global Innovation Accelerator and Korean Startup Showcase

This session introduces NAUGEN, a global life sciences and deep tech accelerator, and its NISA program with George Mason University. Featuring pitches from portfolio startups, it highlights how NAUGEN helps international founders access U.S. capital, partners, and infrastructure to scale globally.

2 PM | TALES FROM THE ROAD

Biotech and MedTech Innovators on their Fundraising Journey

Fundraising has moved to a digital-first "new normal," yet remains challenging. In this panel, entrepreneurs share real-world successes and obstacles, how they identified the right investors, common early-stage misconceptions, and practical lessons and tips for building a more successful fundraising campaign.

3 PM | AI DRUG DISCOVERY 2026

The Rise, The Pivot, and The Pipeline

The discussion will cover the progress made in 2025 and the roadmap for the year ahead, and will bring together active industry, founder, tech, and investor perspectives.

9 AM | NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS

A BREAKTHROUGH FRAMEWORK FOR SMARTER LIFE SCIENCE INVESTING

Rick Berenson, Managing Director of Venzyme Catalyst, introduces a revolutionary way to evaluate early-stage biotech and medtech ventures. Too often, investors rely on "gut" decisions about risk and valuation, while entrepreneurs struggle to communicate their company's true merit—leading to optimistic expectations and missed opportunities. This workshop unveils a powerful framework for improving returns by mapping and managing the entire risk stack, offering investors a clearer, more systematic approach to evaluating strengths, weaknesses, and drivers of success. Whether you are seeking to sharpen your own decision-making or help your team align more effectively, this session will provide insights that immediately change how you view early-stage opportunities. Join us to discover why this breakthrough model is reshaping the rules of life science investing.

Rick Berenson, Executive Committee Member, Mass Medical Angels (MA2), Managing Director of Venzme Catalyst

Rick Berenson will present a practical approach for how family offices can assess early-stage biotech without building a whole internal diligence team. As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the "wisdom of an expert crowd." He'll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.



ABOUT THE BOOK

A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge.

The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies, using a consistent message to achieve compelling results from a fundraising campaign. It teaches you how to aggregate a list of potential global investors that are a fit for your company's products and services. Then it explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.

Raising capital is not a one-time event. It must be an ongoing part of your business strategy. ***The Life Science Executive's Fundraising Manifesto*** reveals the expertise required to continually fundraise and bring your ideas to market.

FOR MORE INFORMATION

Visit www.FundraisingManifesto.com
or visit the Life Science Nation table in the exhibit hall

NOVOTECH™
Biotech's Partner at Every Phase

10 AM | THE FAST LANE TO POC:
LEVERAGING AUSTRALIA AND CHINA FOR SMARTER EARLY CLINICAL DEVELOPMENT

Early-stage biotechs need fast, high-quality data to move from discovery to investment. This workshop shows how Novotech can accelerate your path to First-in-Human and early Proof-of-Concept by strategically leveraging Australia's rapid start-up environment and China's patient-rich ecosystem. You'll see how an integrated early development approach—combining translational strategy, FIH execution, and early patient research—can compress timelines, reduce uncertainty, and deliver the evidence investors look for at seed, Series A, and exit. You'll gain a practical blueprint for designing smarter early studies—translating preclinical findings into a clear FIH roadmap, activating trials quickly in Australia, and accessing targeted patient cohorts in China to generate PoM/PoC data earlier. Walk away with actionable guidance to strengthen your development plan, de-risk your asset, and advance toward clinical proof with confidence.

Marina Mullins, VP Early Clinical Development, Novotech

Marina Mullins is Vice President of Early Clinical Development at Novotech and a registered pharmacist in Australia. She oversees the full early clinical development infrastructure, leading the strategy and execution of programs that advance therapeutic assets from preclinical research through first-in-human studies, with the ultimate goal of supporting clinical proof of concept. Previously, Marina led Novotech's global therapeutic strategy team, providing strategic oversight across oncology, infectious disease, CNS, immune-mediated diseases, and ATMPs. She also managed end-to-end clinical trial delivery at a hematology-focused academic CRO, from protocol design through execution and publication. Earlier in her career, she led pharmacy functions within a Phase I unit, including building and commissioning a GMP clean room and establishing the supporting quality system.

Andy Liu, Managing Director Greater China and Global Labs, Novotech

Mr. Andy Liu has strong operational experience in the CRO industry and a deep understanding of the regional market. Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Before joining PPC group, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of around 500 employees across multiple sites in APAC. Andy holds an MBA from the Booth School of Business at the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.

Carolyn Luscombe PhD, Therapeutic Strategy Manager, Novotech

Carolyn Luscombe PhD is an Early Phase Therapeutic Strategy Manager for Novotech based in Melbourne, Australia. She received a PhD at University of Melbourne in Microbiology and Immunology where she evaluated antiviral drugs for chronic viral infections. Carolyn has 30 years of experience in drug development and 20 years in clinical research and taking products from drug discovery through to Phase 2 studies in Australia and Thailand. She was an Assistant Professor at Colorado State University. She has worked as an executive scientific and clinical development team member in biotech companies in Canada, USA and Australia and has patents for antiviral and immune modulation investigative products. Her specialty is the translation from preclinical studies to first-in-human trials for a broad range of indications and recently focuses on early phase clinical programs for autoimmune, neurological and infectious disease indications for Novotech's local and global clients.

VENTURE VALUATION
GLOBAL VALUATION SERVICES

11 AM | VENTURE VALUATION WORKSHOP
COMPANY VALUATION FOR FUNDRAISING

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland

Dr. Patrik Frei is the founder and CEO of Venture Valuation AG, a company he established in 1999 to provide independent valuation services for high-growth industries. His first client was Novartis Venture Fund, and he has since conducted over 450 valuations for investors, biotech, pharma, and medtech companies. Patrik earned his degree from the University of St. Gallen and completed his PhD at EPFL Lausanne, focusing on the assessment and valuation of high-growth companies. He has served on the boards of Ineo, Aventron AG, and Ophthalmopharma, where he successfully out-licensed a portfolio of products. His articles have been published in journals such as "Nature Biotechnology" and "Chimia," and he has authored business publications. Dr. Frei also lectures on valuation at institutions like Seoul National University, EPFL Lausanne, and the University of St. Gallen, offering workshops globally.

1:00 PM | GLOBAL INNOVATION ACCELERATOR AND PORTFOLIO SHOWCASE

INTRODUCING NISA GLOBAL INNOVATION ACCELERATOR AND KOREAN STARTUP SHOWCASE

NAUGEN Novel Advanced Unprecedented

NAUGEN (www.naugen.com) is a global innovation accelerator focused on advancing groundbreaking technologies and products across life sciences and deep tech. NAUGEN incubates Novel, Advanced, and Unprecedented (NAU) innovations and supports founders in scaling their solutions to global markets. By leveraging its strategy and business development expertise alongside deep scientific and technological insight, NAUGEN cultivates high-potential innovations and companies that remain undiscovered by global markets, accelerating their path toward becoming globally competitive and unlocking exponential value.

NAUGEN recently partnered with George Mason University to launch the Northern Virginia International Soft Landing Accelerator (NISA). This program helps international startups access essential resources — including investor and partner networks, market-entry support, and lab and office space — within one of the fastest-growing U.S. innovation ecosystems. Through NISA, global founders receive strategic mentoring, warm introductions to U.S. capital and corporate partners, and a clear pathway to establish and grow their presence in Northern Virginia's Innovation District. NAUGEN is now recruiting for the NISA 2025–2026 cohort. (https://www.gmu.edu/news/2025-11/new-era-global-growth-george-mason-and-naugen-launch-international-innovation)

This session will introduce NAUGEN and the NISA Program, and feature a pitch showcase highlighting NAUGEN's innovative portfolio and pipeline startups supported through its global acceleration efforts:

- **NexThera (nexthera.org/en/)**
NexThera is a privately held, clinical-stage biotech company developing next-generation treatments for eye diseases and cancer. Its lead program, NT-101, is a first-in-class topical eye-drop therapy for wet age-related macular degeneration (AMD) and has shown encouraging safety and early clinical signals in a U.S. Phase 1/2 study. NT-101 uses a proprietary formulation that allows the medication to remain on the eye surface longer and reach the back of the eye effectively, offering a potential non-injection alternative for patients who currently rely on intravitreal treatments.

- **Karis Bio (karisbio.com)**
Karis Bio is a clinical-stage biotech company developing a first-in-class hiPSC-derived endothelial cell therapy to promote new blood vessel formation for ischemic cardiovascular diseases. The company has established a non-viral, non-integrating reprogramming and xeno-free differentiation platform that produces highly pure (>99%) endothelial cells with long-term safety. Its lead assets target severe peripheral artery disease (PAD) and coronary artery disease (CAD), where preclinical studies have demonstrated robust vascular regeneration and improved tissue perfusion.

- **MedicosBiotech (www.medicosbiotech.com)**
MedicosBiotech is a regenerative biomaterials company developing spider silk protein–based wound care solutions. The company has achieved the world's first scalable production of full-length spider silk protein using E. coli, enabling high-purity and cost-efficient manufacturing. Its lead product, CureSilk, has demonstrated superior healing in chronic wound models, including diabetic foot ulcers and pressure ulcers, outperforming FDA-approved comparators in preclinical studies. MedicosBiotech is expanding its platform toward broader applications in regenerative medicine.

- **ShoeallS (www.shoealls.com/en/)**
ShoeallS is a technology-driven company developing functional and smart medical footwear powered by its proprietary magnetic vibration module, which has been shown to enhance blood circulation and help alleviate pain. Building on its certified medical-device platform, ShoeallS is advancing next-generation smart shoes that integrate self-powering modules, embedded sensors, and AI-based monitoring to enable real-time patient-health insights. The company is expanding from functional footwear into a broader smart healthcare solution.

Join us to learn how NAUGEN and NISA accelerate international innovators — and meet emerging global leaders in biotech and health technology.

LIFE SCIENCE NATION
Connecting Products, Services & Capital

2:00 PM | TALES FROM THE ROAD

BIOTECH AND MEDTECH INNOVATORS ON THEIR FUNDRAISING JOURNEY

The industry has quickly adapted to a "new normal" – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

Greg Mannix, VP of International Business Development, Life Science Nation (Moderator)

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

Derek Sham, Founder & CEO, Cosm Medical

Derek has over 15 years of experience in medical devices. He launched 8+ products including the most utilized urodynamics system in the world used by thousands of urologists on hundreds of thousands of patients culminating in a successful PE-backed exit as a general manager in 2016. He was part of a leadership team as global market director and general manager that scaled a medical device company for eight times return on capital at $640M exit valuation within 4 years. Derek left a high quality corporate MedTech job post-acquisition to create a purpose and profit motivated start-up in women's health that is secured >$9M in investment and non-dilutive funding to modernize female pelvic health.

Martin Cook, CEO, Venstra Medical

Martin Cook is a recognized leader in mechanical circulatory support (MCS) with over 25 years of experience advancing cardiac assist technologies. He previously served as Vice President of Product Development at Sunshine Heart and held key leadership roles at Ventracor (LVAD) and Percutaneous Cardiovascular Solutions (acquired by Edwards). Martin has directed multiple device development programs through CE mark and FDA approval and has advised CEOs and CTOs across the MCS sector as a consultant and mentor to MedTech startup leaders. He holds degrees in Aerospace Engineering and Physics, a PhD in Fluid Mechanics, and is the author of numerous scientific publications as well as the inventor on multiple patents. Martin also contributes to the broader MedTech community as a reviewer for medical technology journals and grant programs.

Vijit Sabnis, Co-Founder, CEO, Adaptyx Biosciences

Vijit focuses on frontier health, renewables, and manufacturing technologies at 1955 Capital, bringing 20 years of experience as an inventor, entrepreneur, and investor. He previously worked with Andrew and Euan as a Partner at Khosla Ventures and was a Co-founder-in-Residence at Deep Valley Labs, a venture incubator founded by QuantumScape CEO Jagdeep Singh. At Khosla Ventures, Vijit invested in and helped build deep tech companies across healthcare, biotechnology, advanced manufacturing, photonics, and sustainability. Earlier, he co-founded and led Solar Junction and was an early employee at Translucent. Vijit holds a Ph.D. from Stanford and a B.S. from UC Berkeley, with multiple publications and patents.

Stéphane Altaba, CEO, Oncovita

Stéphane Altaba is an experienced leader with over 25 years of experience in pharmaceutical firms and biotechnology entrepreneurship. Over the years, Stéphane has made significant contributions to the field of oncology, enabling the introduction of new treatments and diagnostics to patients through strategic partnership. He began his career in R&D, particularly in the development of biotechnological processes at Sanofi, before taking on corporate business development roles at Sanofi and Nordic Pharma. Stéphane Altaba subsequently held various senior management positions, including General Manager of Nordic Pharma Spa in Italy, as well as COO and CEO roles in biotechnology companies such as Genomic Vision, LX Repair and RivelaDX.

3:00 PM | AI DRUG DISCOVERY 2026: THE RISE, THE PIVOT, AND THE PIPELINE

The discussion will cover the progress made in 2025 and the roadmap for the year ahead, and will bring together active industry, founder, tech, and investor perspectives.

Darren Platt, Venture Partner at Magnet Ventures and Chief Data Officer at Montage Bio (Moderator)

Darren Platt has spent his career at the intersection of Genetics and Computer Science, from his early days working on the first percent of the human genome to his current role as Chief Data Officer at Montage Bio. He has held diverse roles, from leading computing at the DOE's Joint Genome Institute to Head of Research at 23andMe when they first launched their product and 15 years designing microorganisms for biomanufacturing at Amyris and Demetrix. At Amyris, Darren oversaw Automation and Computing. At Demetrix, as President, he led the company as it progressed from zero lab space to metric tonne scale production in 4 years. At Exelixis, he developed one of the early computational genomics platforms for model organism-based target identification. He advises the yeast genome database as chair of their SAB, along with a range of companies involved in metabolic engineering, Antibody engineering, data management, small molecule development, and AI-driven fermentation. Holding a Ph.D. in Computer Science, Darren's research has led to groundbreaking developments in genomic data analysis, DNA design languages, Neanderthal DNA sequencing, and various patents covering a wide range of computational molecular biology and bioproduction techniques. http://linkedin.com/in/dplatt

Yue Webster, PhD, MBA, Vice President, Model Driven Drug Discovery Platforms, Eli Lilly and Company

Yue Wang Webster, PhD, MBA, has over 20 years of experience in the pharmaceutical industry. Currently serving as the Vice President of Model-Driven Drug Discovery Playform at Eli Lilly, Yue leads a dynamic team dedicated to delivering cutting-edge technologies for drug discovery. Her team collaborates with scientists on both small molecule and large molecule projects, leveraging Agentic AI and large language models (LLM) to revolutionize drug discovery. Yue is well-versed in the challenges related to data and IT infrastructure, as well as practicalities of scaling AI innovations for enterprise-wide adoption.

Alex Lugovskoy, President and CEO, Diagonal Therapeutics

Alex Lugovskoy is a Co-founder and the CEO of Diagonal Therapeutics and an Entrepreneur-in-Residence at Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts, and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology. http://linkedin.com/in/alexlugovskoy

Georgia Lu, Managing Partner, Magnet Ventures

Georgia Lu, Founder and Managing Partner at Magnet Ventures, has a strong background in M&A, which she has leveraged to guide her venture capital initiatives, particularly in AI-driven biotech. She founded Magnet Ventures in 2016 and has since focused on building a robust portfolio of innovative biotech companies, such as INNFOS (acquired by CloudMinds), HealthTensor, LiliumX, AtomBioworks and Notamab. Her strategic investments are primarily centered around biotechnologies that enhance drug discovery processes, demonstrating her commitment to advancing AI applications in biotech. Under her leadership, Magnet Ventures launched its first biotech-AI focused fund, aimed at supporting groundbreaking developments in the sector.

JANUARY 13 - WORKSHOPS & GLOBAL INNOVATION SHOWCASE

Location: Golden Gate B

9 AM | CHANGING THE LANDSCAPE FOR VENTURE CAPITAL FOR LIFE SCIENCES IN BRASIL

10 AM | LEVERAGING ASIA: HOW TO NAVIGATE ASIAN VC INVESTMENT MANDATES

Asian venture capital firms play an increasingly important role in global life sciences and healthcare investing, yet their mandates, decision processes, and strategic priorities often differ from Western investors. This session demystifies how Asian VCs evaluate opportunities, including geographic requirements, co-investment preferences, and expectations around regional rights, manufacturing, and commercialization. Panelists will share practical guidance on how founders can position their companies to attract Asian capital while preserving long-term strategic flexibility.

11 AM | ISRAEL EXPORT INSTITUTE: ISRAEL COMPANY SHOWCASE

12-4 PM | O2H: CAMBRIDGE X LONDON LIFE SCIENCES SHOWCASE

MEDIA PARTNERS

Want to become a RESI Media Partner? Contact us at Marketing@lifesciencenation.com